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chaptEr 1
gEnEral introduction

chapter 1  11
papi l lomav i r idae
Papillomaviruses are small epitheliotropic DNA-viruses that can induce a wide variety 
of hyperproliferative lesions (papillomas, warts, carcinomas) in the skin and mucosa of 
mammals (rabbit, horse, dog, sheep, deer, elk, cattle, primates and humans) and birds. 
Papillomaviruses are subdivided into different genera (Figure): the human papillomavi-
ruses (HPV) belong to the genera alpha, beta, gamma, mu and nu and include mucosal and 
cutaneous types. 
In 1933, the etiologic agent of cutaneous warts in cottontail rabbits was identified by 
Richard Shope (1) as a transmittable virus later called the cottontail rabbit papillomavirus 
(CRPV). In 1949 Strauss and colleagues (2) were the first to detect viral particles in human 
warts by electron microscopy. Subsequently, at least 100 different full length HPV genomes 
have been described and new types are detected regularly (3-6). A new papillomavirus 
(PV) isolate is recognized as such if the complete genome has been cloned and the DNA 
sequence of the L1 open reading frame (ORF) differs by more than 10% from the closest 
known PV type (4).
HPV are known to be associated with benign anogenital and cutaneous warts (7), as well as 
to be involved in cancer development, in particular with anogenital cancer (8). Most nota-
bly the carcinogenic role of high-risk mucosal HPV in cervical cancer is well established 
and was first proposed in 1976 by Zur Hausen (9), who was recently awarded the Nobel 
Prize for his pioneering work in this area.
A role for HPV in human skin carcinogenesis was suggested even earlier by Jablonska and 
co-workers (10) while working with patients suffering from a rare genodermatosis called 
epidemodysplasia verruciformis (EV) who are at increased risk of cutaneous squamous 
cell carcinoma (SCC). Several HPV types have been found in EV-associated SCC and 
subsequently they have been associated with non-EV SCC in epidemiological as well as 
laboratory studies (11-14). Types from the betagenus (betaPV) appear to be the most likely 
candidates involved in skin carcinogenesis, especially SCC. 
betapapi l lomav i r uses
At present, 31 betaPV-types have been fully sequenced (HPV5, 8, 9, 12, 14, 15, 17, 19, 20, 
21, 22, 23, 24, 25, 36, 37, 38, 47, 49, 75, 76, 80, 92, 93, 96, 98, 99, 100, 104, 105 and 113). 
Based on partial sequences, probably more than 35 new types have to be added to this list 
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of known betaPV types (3;4;15) (Figure). BetaPV DNA can be found in plucked eyebrow 
hairs, skin swabs and skin biopsies, as well as betaPV antibodies being detected in serum. 
detect ion  methods
betapv dna
The presence of betaPV in plucked eyebrow hairs has been used as a measure of betaPV 
infection in several epidemiologic studies. Detection of betaPV DNA in DNA extracted 
from plucked hairs, skin swabs or biopsies is usually performed with polymerase chain 
Chapter 1 
Figure 
Figure. Phylogenetic tree inferred from the L1 nucleotide sequences of the currently known 189 
papillomaviruses. Figure from and legend adapted from (6). 
 
Figure. Phylogenetic tree inferred from the L1 nucleotide sequences of the currently known 189 
papillomaviruses. Figure from and legend adapted from (6).
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reaction (PCR) whereby preferential areas of the genome can be amplified. Next to type-
specific PCRs for betaPV genotypes, several broad-spectrum PCR methods have been 
developed to detect cutaneous HPV-types, species or genera: CPI/IIs (16), FAP59/64 (17), 
F/G (18), modified F/G (MaHa) (19), HPV-type specific PCR (20), degenerate nested PCR 
(21) and PM-PCR (22). Broad spectrum PCR methods can be combined with either cloning 
and sequencing or direct sequencing of the amplimer, but these methods are too laborious 
for large epidemiological studies. On the other hand the development of a reverse hybrid-
ization assay (RHA) in combination with the PM-PCR enables quick and simultaneous 
identification of 25 betaPV types (22). Other detection methods are the APEX (23) and the 
reverse line blotting (RLB) methods (24).
BetaPV antibodies
Antibodies against betaPV proteins can be detected to determine a person’s betaPV sero-
logical status. These antibodies can be detected against the major capsid protein L1 and the 
non-structural protein E6 using HPV-virus like particle (VLP) or GST-HPV fusion proteins 
as antigen in ELISA (12;25) or multiplex (26). The latter method (Luminex®) is a new 
method based on fluorescent bead technology that allows simultaneous detection of anti-
bodies against up to 100 different in situ affinity-purified recombinant HPV proteins (27).
natura l  h is to r y 
acquisit ion and transmission
The betaPV life cycle is closely linked to the biology of the specific host cells, the keratino-
cytes, which are responsible for the renewal, cohesion and barrier function of pluristratified 
epithelia (28). The replication cycle of papillomaviruses is divided into two stages. First, 
the virus is maintained at low copy numbers within the initially infected, but still replicat-
ing cells. The viral proteins E1 and E2 are essential for this basal DNA replication. When 
the basal cells are pushed to the suprabasal compartment, they lose their ability to divide 
and instead initiate the terminal differentiation program. Papillomaviruses replicate in this 
compartment, and for their release into the environment, take advantage of the disintegra-
tion of the epithelial cells that occurs as a consequence of their natural turn-over at the 
superficial layers (reviewed in 29). By extrapolating research done in rabbits regarding 
cottontail Rabbit papillomavirus (CRPV) it is hypothesized that betaPV target stem cells 
are located in the basal layer of the epidermis and in the bulge of the hair follicles (30;31), 
the latter being considered an immune privileged region (30). 
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BetaPV can be found on different parts of the skin, as demonstrated by skin swabs of the 
forehead (17), arms and legs; and by plucked hairs from eyebrows, arms and legs (30;32). 
It is likely that betaPV infection is acquired early in life by close skin contact since children 
appear to be infected with the same cutaneous HPV types as their parents within months 
after birth (33). The exact transmission route of betaPV is unknown but it is hypothesized to 
be transmitted through skin and hair derivates (34). Recent studies have given contradictory 
results however, with one study suggesting that transmission between parents and children 
also occurs at later ages and in adulthood as well (35), while another has suggested that 
transmission occurs rarely between family members (36). The issue of betaPV transmission 
is the topic of Chapter 2, which suggests that close skin contact is the primary means of 
transmission. 
preva lence and per s is tence
dna prevalence
The overall prevalence of betaPV DNA is high, but varies depending on the population, 
anatomic site assessed - whether eyebrow hairs, skin swabs or biopsies of normal skin are 
being sampled - and the method used for detection. Various studies showed a prevalence of 
betaPV, measured by either (multiple) skin swabs or plucked eyebrow hairs from multiple 
sites, to be between 45% and 80% (30;33;34;37). The largest study so far comprised 1405 
persons without skin cancer (845 immunocompetent, 560 immunosuppressed) in 6 coun-
tries (38). The overall betaPV prevalence ranged from 84-91% between immunocompetent 
and immunosuppressed respectively, with HPV23 the most prevalent type. Multiple betaPV 
types per person were often found and there was no predominant type. Only age, and for 
immunosuppressed participants time of immunosuppression, was associated with betaPV 
(38). Sun exposure and skin type were not associated. 
In biopsies from normal skin the prevalence varies between 50% and 80% (39;40). In 
Chapter 3 the intraperson distribution of betaPV DNA in normal skin, perilesional skin and 
SCC biopsies as well as plucked eyebrow hairs is addressed in detail. 
seroprevalence
In the healthy population the betaPV antibody prevalence is around 50-57% (41). Factors 
seen to influence betaPV seroprevalence are increasing age (41;42) and ethnicity (43). A 
Dutch case-control study showed an association between sunburn in the past, especially at 
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age 13-20 years and higher betaPV positivity (44). A higher lifetime sun exposure, how-
ever, was associated with decreased HPV infection. On the other hand, a US case-control 
study showed no significant relations between HPV seropositivity and age, skin sensitivity 
and number of sunburns (26). In Chapter 4 it is also shown that sunburn does not initiate 
the betaPV antibody response. 
persistence
Persistence of viral DNA is considered an important aspect of mucosal HPV infections 
in relation to cervical carcinogenesis (45). Recent studies indicate that also betaPV DNA 
infections persist. In a small cohort of 23 healthy adults it was demonstrated that the major-
ity of detected betaPV infections persisted for up to 2 years (46). Eyebrow hairs were 
plucked at 8 time-points over 2 years and showed that 74% of the participants had at least 
one persisting infection. Another recent study showed persistent betaPV DNA positivity 
in 48% of the 42 healthy individuals after 7 years (37). It is unknown whether persistence 
plays a role in the betaPV related carcinogenesis and this issue is the topic of Chapter 5.
No previous studies have involved the persistence of betaPV L1 antibodies, while in Chap-
ter 5 we saw that antibodies are stable over 8 years, with 89% of people remaining antibody 
positive or negative.
disease assoc ia t ions
Epidermodysplasia ver ruciformis
EV was first described in 1922 by Lewandowsky and Lutz (47) as a disease where patients 
develop pityriasis versicolor-like lesions and flat warts as well as numerous SCC, but not 
basal cell carcinomas (BCC), on sun-exposed sites at a young age. In the SCC of EV patients 
mainly betaPV types 5 and 8 are found (48). Recently it was shown that EV-patients harbor 
multiple betaPV types in both eyebrow hairs and skin biopsies (49) with viral loads ranging 
from less than 1 betaPV copy per 100 cells up to 400 copies per cell.
Genetic studies in EV patients worldwide have shown mutations in two genes, EVER 1 
and 2, to be involved. EVER genes are members of a transmembrane channel-like (TMC) 
gene family. The function of TMC proteins is still unknown, but it has been proposed that 
they could constitute a novel group of ion-transporters or channels or modifiers of such 
activities, and could be involved in signal transduction (reviewed in 28). Recent research 
16  chapter 1
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chapter 1  17
suggests that EVER-defects in zinc-metabolism may also play a role in the susceptibility of 
EV-patients to HPV-infections (50;51).
Keratinocyte skin cancer
Keratinocyte skin cancer is a common malignancy in mainly Caucasian populations, 
consisting of BCC and SCC and several epidemiological studies have investigated the 
association between markers of HPV infection, in particular betaPV infection, and kera-
tinocyte skin cancer. Although basal cell carcinomas (BCC) are the most common kerati-
nocyte skin cancer, no clear associations with betaPV DNA or antibodies have been found 
(16;25;26;41;52-54).
Studies that have investigated the role of betaPV DNA, detected in eyebrow hairs and 
skin biopsies, in the development of AK and SCC are summarized in Table 1. Associa-
tions have been found between the presence of betaPV DNA and AK (12;55;56) and SCC 
(12;19;53;57), but no specific high risk types were identified. 
Studies investigating the association between antibodies against betaPV and AK or SCC 
are summarized in Table 2. Seroreactivity to betaPV L1 was associated with AK and SCC 
in a number of studies (12;26;53;54;58-61) and the presence of AK was inversely associ-
ated with seroreactivity to betaPV E6 (12). E6 and L1 antibodies were hardly ever found 
concomitantly, suggesting that antibody responses to the early (non-structural, intracel-
lular) and late (structural, also extracellular) betaPV proteins take place at different times 
and phases during betaPV infection or betaPV-associated tumor development (12). It was 
also shown that HPV DNA positivity and L1 seropositivity were correlated, and E6 sero-
positivity was inversely correlated with HPV DNA positivity, somewhat in line with the 
hypotheses either that E6 antibodies partly protect against SCC or that SCC patients have 
difficulties inducing immune responses to cutaneous HPV E6 proteins (12;57). 
Individuals in subtropical areas have an increased risk of actinic keratoses (AK) and 
keratinocyte skin cancer, since the principal causal factor is excessive exposure to solar 
UV radiation (62-64). Because betaPV is a possible cofactor in the development of AK 
and SCC in Queensland, Australia, where reported incidence rates are the highest in the 
world (65), a number of studies have been performed to investigate the role of HPV in 
the development of keratinocyte skin cancer (12;19;55;56). These were performed within 
the Nambour Skin Cancer study, a longitudinal cohort study in subtropical Queensland, 
18  chapter 1
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Australia, that started in 1986 with the enrollment of 2095 participants (66) who were 
then followed up until 2007. All studies described in this thesis have been performed in 
Australian participants, Chapters 2, 4, 5 and 6 as part of the Nambour Skin Cancer Study 
and Chapter 3 in a small cohort of SCC-patients in Northern Queensland.
scope o f  th is  thes is
Chapter 2 describes the transmission of betaPV between opposite-sex partners as com-
pared with age and sex matched controls.
Chapter 3 describes the distribution of betaPV as measured in eyebrow hairs and biopsies 
of normal skin, SCC tumor tissue and perilesional skin of 21 SCC-patients.
Chapter 4 describes the relation between two frequently used markers for betaPV research: 
betaPV DNA in eyebrow hairs and betaPV antibodies from serum, both cross-sectionally 
and longitudinally.
Chapter 5 describes the association between persistent betaPV infection as indicated by 
viral DNA in eyebrow hairs and the risk of AK on the whole body and on the face. 
Chapter 6 describes the association between betaPV antibodies in serum and the develop-
ment of SCC in a longitudinal study.
Chapter 7 comprises the general discussion and conclusions. 
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abst ract
Betapapillomaviruses may be associated with the development of cutaneous squamous cell 
carcinoma but little is known about their transmission. One suggestion is that they are 
transmitted through close skin contact.
To test this hypothesis we assessed whether co-habiting opposite-sex couples were more 
or less likely to share betaPV types than each member of the couple and an age-matched, 
opposite-sex control. Betapapillomavirus was measured in eyebrow hairs of 57 couples and 
114 age- and sex-matched controls. We compared the proportion of partners who shared at 
least one betaPV type with the proportion of control partnerships sharing a betaPV type. 
We further subdivided those who shared at least one type into those who shared only one 
and those who shared more than one. We tested the significance of differences in these 
proportions using Chi-squared tests. A case-wise concordance index was used to calculate 
the overall concordance of the partners and the control pairings.
At least one betaPV type was shared by 39% of the co-habiting couples and 26% of the 
control pairs (p=0.10). When restricted to all people with at least one virus infection (26 
couples) 74% of the partners and 46% of the control pairs shared at least one type (p=0.02). 
The case-wise concordance index for partners was 0.28 (95% CI 0.21-0.35) and for the 
matched control pairs 0.16 (95% CI 0.12-0.20) (p<0.001). 
Our results support the hypothesis that skin-to-skin contact is the primary means of beta-
papillomavirus transmission.
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in t roduct ion
Human papillomaviruses of the beta-genus (betaPV) are cutanotropic viruses that are 
associated with cutaneous squamous cell carcinoma (SCC) (1). So far 31 different betaPV 
types have been fully sequenced and more than 100 types partially sequenced (2;3). Epi-
demiological studies have shown that all currently identified betaPV types are frequently 
found in hair bulbs of eyebrows and body hairs, normal skin swabs and biopsies from 
healthy controls and transplant recipients, as well as in tumour tissue from patients with 
SCC (4-6). Usually multiple infections are detected within a sample (7).
Little is known about the transmission of betaPV. In healthy people no clinical signs of ini-
tial infection are observed. We have found only 5 previous studies addressing transmission 
of betaPV, several of which are very small (8-12). The data about transmission between 
parents and children is ambiguous: one study involving 38 infants showed parents and 
babies as young as 4 weeks of age to share betaPV types (8) and another study showed that 
transmission between parents and children occurs frequently (13;14). However in a third 
study transmission between parents and children was observed rarely (15). In this cohort 
transmission between couples was also infrequently seen (15). A cohort of 23 participants 
showed that the 5 students sharing a household were not likely to obtain each other’s 
betaPV, but instead kept their own infection profile (10). Despite different outcomes, all of 
these studies concluded that betaPV transmission probably takes place during close (skin-
to-skin) contact.
To test this hypothesis we assessed whether co-habiting married or de facto opposite-sex 
couples (herein called ‘partners’) were more or less likely to share betaPV types than each 
member of the couple and an age-matched, opposite-sex control. 
mater ia l  and methods
study population and sample collection
Participants were an unselected subset of the study population of the Nambour Skin Cancer 
Study which has been described in detail previously (16;17). Briefly, in 1986, 2095 of 3000 
randomly selected residents of Nambour, a subtropical township in Australia (latitude 26°S), 
who were aged 20-69 years, participated in a skin cancer prevalence survey. From 1992 to 
1996, 1621 of these took part in a trial of sunscreen application and beta-carotene supple-
mentation for the prevention of skin cancer. In 1996, 507 randomly selected members of the 
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cohort participated in a sub-study aiming to understand the association between HPV and 
skin cancer (18), and 10 eyebrow hairs were plucked from each participant and processed 
as described below. Participants’ relationships with one another in 1996 were recorded. For 
the analysis described here we selected all 57 male-female co-habiting couples. For each 
of these 114 people, we randomly selected an opposite-sex control from the remaining 393 
participants, matched to the age of his/her partner. For example, a 60-year-old man and his 
50-year-old wife were matched to a 50-year-old woman and a 60-year-old man respectively. 
dna isolation, pcr and hybridization
DNA from eyebrow hairs was isolated according to a method described previously (19). 
BetaPV detection and genotyping were performed using a reversed hybridization assay as 
described previously (20). All amplimers generated with the broad spectrum PCR were 
analysed with a reverse hybridization assay (RHA) that permitted specific detection and 
identification of 25 established betaPV genotypes (i.e., 5, 8, 9, 12, 14, 15, 17, 19-25, 36-38, 
47, 49, 75, 76, 80, 92, 93 and 96). The RHA was performed according to the manufacturer’s 
instructions (skin (beta) HPV prototype research assay; Diassay BV, Rijswijk, The Neth-
erlands). 
statist ical analyses
We compared the proportion of partners who shared at least one betaPV type with the 
proportion of control partnerships sharing a betaPV type. We further subdivided those who 
shared at least one type into those who shared only one and those who shared more than 
one. We tested the significance of differences in these proportions using Chi-squared tests. 
These analyses were performed for all participants and for those in whom we identified at 
least one betaPV. In addition, case-wise concordance was calculated, which is defined as the 
conditional probability that one member of the matched pair is positive to a specific betaPV 
type given that the other member is positive. It was estimated as the ratio of the number of 
concordant pairs to the total of concordant and average discordant pairs. The standard error 
and 95% confidence interval were estimated according to methods documented by Huang 
and Tai (21). The totals for concordant and discordant pairs have been pooled across the 25 
individual betaPV types. One estimate was calculated for partner pairs and a second for the 
pairs formed by matched control couples. Statistical analyses were performed in SAS 9.1. 
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resu l ts
The mean age of the men was 55 years (SD 11) and of the women 51 (SD 11). Seventy-four 
percent of the male partners were betaPV-positive (median number of types: 2, range 1-12), 
compared with 86% of the male controls (p=0.07) (median number of types: 2, range 1-15), 
70% of the female partners (median number of types: 2, range 1-11) and 74% of the female 
controls (p=0.65) (median number of types: 1, range 1-11). 
At least one betaPV type was shared by 39% of the co-habiting couples (Table). For the 
control pairs this was 26% (p=0.10). Fourteen percent of partners versus 11% of control 
pairs shared more than one type (p=0.25). When we repeated the analyses for all people 
with at least one virus infection (26 couples) 74% of the partners and 46% of the control 
pairs shared at least one type (p=0.02), and 32% versus 19% shared more than 1 type 
(p=0.08) (Table). The case-wise concordance index for partners was 0.28 (95% CI 0.21-
0.35) and for the matched control pairs 0.16 (95% CI 0.12-0.20) (p<0.001). 
Table: Number of betaPV types shared by partners and by partners and their controls.
No. of shared types Partners, n=57
N (%)
Control-pairs, n=114
N (%)
 Including all 
participants 
0 35 (61) 84 (74)
1+ 22 (39) 30 (26)
Chi-square 2.71 (p=0.10)
  
0 35 (61) 84 (74)
1 14 (25) 18 (16)
>1 8 (14) 12 (11)
Chi-square 2.79 (p=0.25)
No. of shared types Partners, n=26
N (%)
Control-pairs, n=52
N (%) 
 Including only betaPV 
positive participants
0 7 (26) 28 (54)
1+ 19 (74) 24 (46)
Chi-square 5.08 (p=0.02)
  
0 7 (26) 28 (54)
1 11 (42) 14 (27)
>1 8 (32) 10 (19)
Chi-square 5.08 (p=0.08)
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d iscuss ion
In this study we found that participants more often shared at least one betaPV type with 
their opposite-sex domestic partner than with random controls of the same age and sex as 
their partner. This difference was significant when the analysis was restricted to people 
who had at least one betaPV infection. Partners also were likely to share more than one 
type than control pairs, although due to small numbers significant differences could not be 
observed. We found a highly significant difference in the concordance index. We assessed 
skin type, sun exposure and skin cancer rate as possible confounders and found no differ-
ences between the male and female partners and male and female controls. The borderline 
significant difference in betaPV prevalence between the male partners and male controls is 
most likely to be due to random sampling error and is not likely to have caused differences. 
The higher number of viruses seen in male controls than in male partners suggests that they 
would have an increased chance of sharing types with the female partner, so if anything, 
this variability may have led to an underestimation of the difference in shared types found.
The most likely explanation for our findings is the frequent close contact likely to occur 
between partners, which was also postulated to be the main cause of HPV transmission 
in babies (8). A study among tenants in a student share house showed that transmission 
was rare (10), suggesting that living in close proximity may not be sufficient for betaPV 
transmission and skin-to-skin contact may be required. A recent study about betaPV trans-
mission in families with an overall HPV prevalence of 42% found that the frequency of 
shared types was higher among couples than among randomly selected individuals, but the 
frequency of sharing at least one type was only 21% and in all cases only one type was 
shared (15). We found a much higher proportion of couples with at least one shared type 
(39%), and 14% of these shared more than one type, possibly due to the higher overall 
prevalence of betaPV in our sample. The higher prevalence might be due to the fact that 
we used a different PCR and typing method than those used by Gottschling and colleagues 
(15). Furthermore, the mean age of our participants was higher (over 50 compared with 
42 years), and age is independently associated with betaPV acquisition or detection (7). 
Weissenborn and colleagues studied the betaPV- spectrum in 10 families with up to 3 gen-
erations sampled over a period of time and found comparable results to ours with respect 
to partner transmission, despite using skin swabs rather than eyebrow hairs as the sample 
for viral DNA detection (22). Their longitudinal measures showed that persistent infections 
in one person of a family were shared by their family members in 30-50% of the cases. 
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Our data are cross-sectional and we therefore cannot address the issue of whether or not 
persistent betaPV types are shared between couples.
In conclusion, these cross-sectional data demonstrate that co-habiting partners of the 
opposite-sex share a greater number of betaPV types than with randomly selected matched 
members of the population. This finding supports the hypothesis that close contact is the 
primary means of betaPV transmission, probably through skin-to-skin contact. Larger, 
longitudinal studies are needed to confirm this finding and to give more insight into the 
sustainability of the shared infections. 
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abst ract
Human papillomaviruses from the genus beta (betaPV) are a possible cause of cutaneous 
squamous cell carcinoma (SCC). We compared the betaPV infections in SCC and in sets 
of cutaneous tissues collected from a series of individual SCC patients to determine con-
cordance, and to assess the adequacy of eyebrow hairs as non-invasive markers of betaPV 
infection. Biopsies of SCC tumours, perilesional tissue, normal skin from the mirror image 
of non-facial SCC and plucked eyebrow hairs were collected from 21 patients with incident 
SCC living in Queensland, Australia. These were tested for the presence of DNA from 25 
different betaPV types. Overall prevalence of betaPV was high in every sample type, rang-
ing from 81-95%. The median number of types was significantly higher in the SCC tumour 
(6), perilesional skin (5) and eyebrow hairs (5) than in normal skin (2). Comparing SCC tis-
sue with other sample types within patients showed 63 overlapping infections with eyebrow 
hairs (71%; 95%CI 60-80); 56 with perilesional skin samples (63%; 95% CI 52-73) and 23 
with normal skin samples (26%; 95% CI 17-36). The sensitivity of eyebrow hair testing for 
detection of betaPV in the tumour was 82% (95%CI 57-96) with concordance defined as 
50% of betaPV types in common and 29% (95%-CI 10-56) for 100% concordance. 
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in t roduct ion
Infection with human papillomaviruses (HPV) from the beta-genus (betaPV) is associated 
with the development of actinic keratoses (AK) and squamous cell-carcinoma (SCC) in 
immune-competent persons as well as in organ transplant patients (1-7) The majority of 
people are infected with multiple betaPV (8), and a substantial proportion of these infec-
tions remains detectable over time, indicative of persistent infection (9;10).
Different mechanisms by which betaPV play a role in carcinogenesis have been proposed, 
for example the “hit-and-run” hypothesis, whereby betaPV act early in carcinogenesis and 
is not necessary for maintenance of the malignant phenotype (11;12). BetaPV may act 
within or contribute to field cancerisation where a discrete area of tissue is at increased 
risk of developing cancer (13), as seen for SCC of the oesophagus (14) and cutaneous 
actinic keratoses (15-18). A postulated mechanism of transformation is betaPV-mediated 
impairment of host cell defenses against excessive sun light exposure, such as inhibition of 
DNA repair and apoptosis (19-21).
In epidemiological studies, the presence of betaPV DNA in eyebrow hairs, skin swabs, and 
normal skin biopsies have all been used as markers of betaPV-infection (22-26). Which of 
these is the most appropriate indicator of the betaPV types found in the tumour and/or the 
surrounding area is currently unknown. It has been proposed that the hair follicle is the 
natural reservoir of cutaneous HPV (22;27) with support from studies showing that HPV 
is present in hair follicles obtained from different body sites such as scalp, eyebrow, arm, 
trunk, leg and pubic region (22;28).
Here we have investigated within a series of SCC patients the prevalence and distribution 
of 25 different betaPV types in sets comprising four sample types (SCC, perilesional skin, 
normal skin on the mirror image site of the SCC, and plucked eyebrow hairs) to gain 
possible insights into viral pathogenesis of SCC and assess if plucked eyebrow hairs are 
indeed sentinel for betaPV present in the tumour. 
mater ia l  and methods
study population and sample collection
This study took place in Townsville, a regional town in tropical Australia (latitude 190S). 
Patients, with diagnosis of histologically confirmed incident primary cutaneous SCC 
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between April 2002 and April 2003 were recruited from the Townsville Hospital by local 
specialist doctors and general practitioners. Ten eyebrow hairs were plucked from each 
participant using sterile tweezers and gloves, and biopsies were collected from the SCC, 
perilesional skin immediately adjacent to the SCC and normal skin from the mirror image 
site of the SCC. Because of ethical, cosmetically reasons, for the patients with a facial 
SCC (n=3) a biopsy of the forearm was used as normal skin. All samples were snap frozen 
and stored at -70°C. Age, sex and information about sun exposure were recorded for all 
participants. The study was approved by the ethics committee of James Cook University 
and by the Townsville Health Service District Institutional Ethics Committee.
dna isolation, pcr and hybridization
DNA from eyebrow hairs and biopsies were isolated using a QIAamp DNA mini kit 
(Qiagen). Briefly, hairs and biopsies were pre-treated overnight with proteinase K solu-
tion according to the manufacturer’s instructions. After lysis with 200 ul AL buffer, half 
of the volume was stored at -70oC, whilst the other half was processed according to the 
manufacturer’s instructions. 
BetaPV detection and genotyping were performed using a reversed hybridization assay as 
described before (23). Briefly, PM-PCR was performed in a final reaction volume of 50 
ul, containing 10 ul of the isolated DNA, 2.5 mM MgCl2, 1x GeneAmp PCR buffer II, 0.2 
deoxynucleotide triphosphates, 1.5 U AmpliTaq Gold DNA polymerase and 10 ul of the 
PM primer mix. The PCR was performed by a 9 min pre-heating step at 94oC, followed 
by 35 cycles of amplification comprising 30 s at 94oC, 45 s at 52oC, and 45 s at 72 oC. 
The PCR was ended by a final elongation step at 5 min at 72 oC. All amplimers were 
subsequently analyzed with a reverse hybridization assay (RHA) that permitted specific 
detection and identification of the 25 established betaPV genotypes (i.e. 5, 8, 9, 12, 14, 15, 
17, 19-25, 36-38, 47, 49, 75, 76, 80, 92, 93 and 96). The RHA was performed according 
to the manufacturer’s instructions (skin (beta) HPV prototype research assay; Diassay BV, 
Rijswijk, The Netherlands). 
statist ical analyses
We calculated the prevalence of betaPV DNA in each sample type, defining a sample as 
positive if it had at least one betaPV type detected. The number of viruses detected per 
sample was calculated. We calculated the Friedman test, to test for significant overall dif-
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ferences in the median number of betaPV types between the four sample types. Wilcoxon 
tests were used to estimate the significance of differences between any two sample types. 
Overall betaPV agreement was defined as the proportion of cases where both samples being 
compared were either betaPV-positive or -negative. To compare the number of types in 
common between the SCC tissue and other samples obtained from each patient, we derived 
the proportion of the total number of infections found in SCCs (type-specific per patient 
and summed across all participants) that were also found in normal skin, perilesional skin 
and hairs, respectively.
We estimated the sensitivity of testing hair follicles for betaPV DNA, using SCC tissue as 
the reference. We first calculated sensitivity assuming that for the test to be classified as 
‘positive’, 100% of the types found in the SCC also had to be detected in the hair follicles. 
We then recalculated sensitivity with test concordance defined as 50% of the types in com-
mon between SCC and hair follicles. Finally we repeated the sensitivity analyses taking as 
the reference the perilesional field of skin adjacent to the SCC rather than the SCC itself.
Analyses were performed in SPSS 14.0 and SAS 9.1.
resul ts
Patients participating in this study were an unselected sample of 37 patients with SCC who 
had other tissue samples, next to the SCC, collected and available for analysis. We included 
only those 21 participants for whom complete sample sets were available. The mean age of 
these patients was 71 years (range 35-87) and 80% were males. 
betapv presence and prevalence
An overview of all betaPV types found in the four different samples of all 21 SCC cases 
is shown in Table 1. Only one SCC patient (# 1) was entirely betaPV negative, with no 
betaPV DNA detected in any of his samples. 
BetaPV DNA was found in the eyebrow hairs of 18 SCC patients (86%), and the median 
number of types found per patient was 5 (inter quartile range (IQR) 2-10) (Table 2). 
BetaPV DNA prevalence was 81% in biopsies of both normal skin and SCC, but more types 
were found in the tumour (median 6) and in eyebrow hairs (median 5) than in normal skin 
(median 2) (p values 0.016 and 0.001 respectively). Perilesional biopsies had the highest 
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Table 1. Individual sample listed with all betaPV types detected.
Individual Age Sex Sample betaPV types
no of 
types
1 35 male eyebrow hairs Negative 0
normal skin Negative 0
perilesional skin Negative 0
SCC (forearm) Negative 0
2 58 male eyebrow hairs 8* 9 15 22 24 36 37 38 49 93 10
normal skin 9 22 24 38 4
perilesional skin 9 24 36 38 93 5
SCC (forehead) 8 9 15 22 24 36 38 49 93 9
3 59 male eyebrow hairs 8 9 12 15 17 19 20 23 36 38 49 75 80 92 14
normal skin 9 15 17 49 4
perilesional skin 9 12 15 17 20 22 23 36 38 75 80 11
SCC (scalp) Negative 0
4 60 male eyebrow hairs 8 15 22 49 80 5
normal skin 36 80 96 3
Perilesional skin 15 22 36 80 4
SCC (upper arm) 15 22 36 3
5 61 male eyebrow hairs 5 19 23 37 75 76 80 7
normal skin Negative 0
perilesional skin 5 15 17 19 23 36 75 76 92 9
SCC (forearm) 5 9 14 15 19 23 75 7
6 65 male eyebrow hairs 20 36 38 3
normal skin Negative 0
perilesional skin 5 8 9 17 20 22 23 36 38 92 10
SCC (lower leg) 93 1
7 68 male eyebrow hairs 9 17 20 22 80 5
normal skin 20 1
perilesional skin 9 14 19 20 23 24 36 38 80 93 10
SCC (hand) 9 17 20 22 38 93 6
8 70 male eyebrow hairs Negative 0
normal skin 49 1
perilesional skin 20 1
SCC (arm) 15 20 92 2
9 70 male eyebrow hairs 9 15 23 92 4
normal skin 9 15 2
perilesional skin 9 15 17 23 92 96 6
SCC (hand) 9 15 23 49 92 96 6
10 71 male eyebrow hairs
5 8 9 14 15 17 19 21 23 25 36 49 76 92 
93 96 16
normal skin 5 8 23 25 4
perilesional skin 5 8 9 14 15 17 19 21 23 25 36 92 12
SCC (shin) 8 17 2
11 71 male eyebrow hairs 15 23 24 38 76 96 6
normal skin 23 1
perilesional skin 8 15 21 22 23 24 93 96 8
SCC (thigh) 96 1
12 72 female eyebrow hairs 15 17 22 80 93 5
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betaPV prevalence (95%) with a median number of types of 5, which was also significantly 
higher than in normal skin (p<0.001) (Table 2).
Individual Age Sex Sample betaPV types
no of 
types
normal skin 22 80 93 3
perilesional skin 9 14 24 25 80 92 93 7
SCC (upper arm) 5 17 22 23 80 93 6
13 73 male eyebrow hairs 17 1
normal skin 15 75 2
perilesional skin 9 15 17 23 4
SCC (forearm) 9 15 17 19 23 38 6
14 76 female eyebrow hairs 5 9 17 23 24 25 36 37 38 76 92 96 12
normal skin 5 24 49 3
perilesional skin 24 92 2
SCC (forearm) 5 9 17 24 25 76 92 96 8
15 77 male eyebrow hairs 15 23 75 93 4
normal skin Negative 0
perilesional skin 5 15 17 23 36 75 93 96 8
SCC (forearm) 5 15 23 38 75 93 6
16 77 male eyebrow hairs 92 1
normal skin 17 36 92 96 4
perilesional skin 9 17 19 92 96 5
SCC (forearm) negative 0
17 78 male eyebrow hairs 9 15 17 22 23 36 49 93 8
normal skin 17 1
perilesional skin 15 23 49 96 4
SCC (post ear) 15 49 2
18 82 female eyebrow hairs 5 15 17 23 37 93 6
normal skin 5 17 2
perilesional skin 5 17 23 93 4
SCC (ankle) 5 15 17 23 76 93 6
19 82 male eyebrow hairs 8 12 15 17 23 24 37 38 75 92 93 11
normal skin 12 15 17 22 23 37 38 49 96 9
perilesional skin 8 9 12 15 17 21 23 24 37 38 75 92 93 96 14
SCC (shoulder) 12 15 17 23 38 75 92 93 96 9
20 83 male eyebrow hairs 9 17 19 22 36 38 49 92 93 96 10
normal skin 15 17 2
perilesional skin 9 76 96 3
SCC (lower leg) 19 21 22 24 76 92 93 96 8
21 87 female eyebrow hairs Negative 0
normal skin 15 23 2
perilesional skin 15 1
SCC (heel) Negative 0
*Bold types are types shared between different samples of the same patient.
Table 1 continued
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Overall, the prevalence of most individual betaPV-types was lowest in normal skin, except 
for HPV37 and 80 where the prevalence was lowest in the SCC biopsies and for HPV 49 
that was lowest in perilesional skin. The most prevalent types across all tissue samples were 
HPV15, HPV17 and HPV23 (Table 3). 
comparisons between scc, peri lesional and normal skin biopsies
We observed a high degree of overlap between the betaPV types in the different samples 
from each patient (Table 1). No type was found exclusively in any of the samples, including 
SCC, when betaPV type distribution was compared.
Overall betaPV agreement (having both samples concordant for the presence or absence of 
betaPV, irrespective of type) between tumour tissue and perilesional skin was 86% (18/21; 
95%CI 64-97), and between tumour tissue and normal skin was 71% (15/21; 95%CI 48-89).
A total of 128 betaPV infections were found in the eyebrow hairs of the 21 participants, 48 
in normal skin biopsies, 128 in perilesional biopsies and 89 in tumour tissue biopsies (Table 
3). Of the 89 betaPV infections found in tumour tissue, 56 infections with the same betaPV 
type were also found in the perilesional skin of the same patient (56/89, 63%; 95%CI 
52-73). In comparison, 23 overlapping infections were observed between SCC and normal 
skin, a proportion of 26% (23/89; 95% CI 17-36). There were 33 overlapping infections 
between perilesional skin and normal skin (26%, 33/128; 95% CI 19-34). 
betapv in eyebrow hairs as marker of betapv infection in scc
Overall betaPV agreement was 86% between eyebrow hairs and tumour tissue and 90% 
between hairs and perilesional skin. Of the 89 betaPV infections found in SCC tissue, 63 
type-specific infections were also found in the eyebrow hair follicles of the same patient 
63/89, 71%; 95% CI 60-80) and 79 overlapping infections were detected between perile-
sional skin and eyebrow hairs (79/128, 62%; 95% CI 53-70). 
Table 2. Overall betaPV detection in samples of SCC-cases.
 (N=21)
 eyebrow hairs normal skin
perilesional 
skin SCC
Detection of betaPV, n (%)
positive 18 (86) 17 (81) 20 (95) 17 (81)
median no betaPV types (IQR*) 5 (2-10) 2 (1-4) 5 (4-10) 6 (1-7)
range 0-16 0-9 0-14 0-9
*IQR: Inter quartile range
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In three individuals SCC was present on the face (# 2, 3, 17 in table 1). In the two betaPV 
positive SCC (# 2 and 17) all types present in the SCC were also found in the eyebrow hairs 
of the corresponding individuals. 
When we defined hair samples as being concordant if they contained all of the types found 
in the SCC biopsy, sensitivity was 29% (95%-CI 10-56). Using a less stringent definition 
of concordance whereby hair samples were classified as concordant if they contained 50% 
of the betaPV types found in the SCC, sensitivity was 82% (95% CI 57-96). When the 
perilesional skin was taken as the reference category (instead of SCC tissue), sensitivities 
for these comparisons were 25% (95% CI 9-50) and 65% (95% CI 41-85) respectively. 
Table 3. BetaPV prevalence in 21 SCC patients shown per sample.
HPV-type (N=21)
 eyebrow hairs normal skin perilesional skin SCC
5 4 3 5 5
8 5 1 4 2
9 8 3 11 6
12 2 1 2 1
14 1 0 3 1
15 11 6 11 10
17 10 6 10 7
19 4 0 4 3
20 3 1 4 2
21 1 0 3 1
22 6 3 4 5
23 10 4 12 7
24 4 2 6 3
25 2 1 2 1
36 7 2 8 2
37 5 1 1 0
38 7 2 5 5
47 0 0 0 0
49 6 4 1 3
75 4 1 4 3
76 4 0 2 3
80 5 2 4 1
92 7 1 8 5
93 8 1 7 8
96 4 3 7 5
Total no 
infections 128 48 128 89
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d iscuss ion
In this study we systematically explored and compared type-specific betaPV prevalence 
and distribution in sets of four different tissue samples taken from 21 incident SCC patients. 
The overall betaPV DNA positivity was high, ranging from 81% in normal skin and 
SCC tissue to 86% in the eyebrow hairs and 95% in perilesional skin. These percentages 
underscore the ubiquity of cutaneous betaPV infections that has been previously reported 
(8;9;29). The multiplicity of infections was also found to be high, with a median number of 
infecting types of 5 in eyebrow hairs and perilesional skin and 6 in the tumour, and up to 14 
and 16 different betaPV types present in single samples from perilesional skin and eyebrow 
hair, respectively. The number of betaPV types detected in normal skin was considerably 
less than in the other tissues, in support of previous data showing that normal skin has 
fewer betaPV types than SCC tissue (30;31).
The lower number of betaPV types found in normal skin than in the tissue near the SCC 
supports the hypothesis that perilesional skin represents an area of field cancerisation from 
which the tumour arose (15-18). The localised presence of betaPV may have contributed to 
the field change, in conjunction with other factors such as sunburn or chronic sun exposure. 
Alternatively focal damage may have enhanced betaPV infection, increasing the viral load 
above the detection limit of the test, or less likely, may have rendered the affected skin 
more susceptible to infection with betaPV. We obtained the normal skin biopsies from the 
mirror image site of the SCC so that betaPV detection would be unconfounded by local 
photo immune suppression or to stimulation of viral replication by UV irradiation.
Although we found the same median number of betaPV types in perilesional and SCC 
tissue, a different spectrum of types was seen, as shown by the measures of type-specific 
agreement. Hypothetically the types present in the perilesional skin could partially rep-
resent commensal types, whereas those in the tumour could be associated with tumour 
formation. However, when we compared all tumours and non-tumour tissues no particular 
betaPV types stood out as occurring in the tumour alone or in healthy tissue alone, making 
the identification of specific oncogenic types unlikely. These results show, however, that 
it is unlikely that the betaPV DNA found in the perilesional skin was due to carry-over of 
viral DNA from the tumour, since distinct differences were found between these tissues. 
With this small study size, random variation may also have contributed to the differences 
in betaPV types between tissue types.
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The detection of betaPV in eyebrow hairs has been used in epidemiological studies as a 
marker of infection, not only because the bulb is regarded as a reservoir of infection but 
also because of the ease of obtaining eyebrow hairs. The greater diversity of types found 
in hair follicles compared with normal skin lends support to the notion that hair follicle 
is a reservoir for betaPV (22), with the epidermal stem cells residing in the bulge as the 
probable main site of persistent infection. 
We compared betaPV DNA in eyebrow hairs with biopsies of the SCC and perilesional skin 
to obtain information about the comparability of these samples. The type-specific agree-
ment was slightly higher for SCC than for perilesional skin. To calculate the sensitivity 
of eyebrow hair follicle testing as a measure of relevant betaPV infection, we first took 
SCC-tissue as the reference tissue. The sensitivity ranged from 25-82% depending on the 
definition of concordance and whether the SCC or the perilesional tissue is used as the 
reference. The relevance of the high agreement in the two individuals with a betaPV posi-
tive SCC present on the face needs to be explored further in larger datasets given the small 
number of participants. Although eyebrow hairs are frequently used as markers of infection 
in betaPV studies, it is notable that substantial differences can exist between type-specific 
detection rates in SCC tumour and eyebrow hairs of individuals. 
Two other studies have also compared HPV DNA in tumours of SCC patients with HPV 
DNA found in other specimens (32;33). Compared to the previous studies, our overall 
detection rate of HPV DNA was much higher for all skin samples, although the higher 
number of types in SCC biopsies than in normal skin was found in all three studies. The 
differences may be due to different DNA isolation and typing methods and different study 
populations. In contrast, the overall betaPV DNA detection rate in eyebrow hairs in our 
study and that conducted by Rollison and colleagues was similar (33). It may be that betaPV 
loads in eyebrow hairs exceed those in the skin samples, making analysis of eyebrow hair 
follicles less susceptible to differences in sensitivity due to differences in betaPV DNA 
isolation and detection methods. The proportion of participants in whom both tumour tissue 
and normal skin biopsies were betaPV positive was also similar between these two studies, 
at around 75%. However Rollison and colleagues did not appear to take individual betaPV 
type-specificity into account (33). Asgari and colleagues could not perform intra-patient 
comparisons between normal and affected skin, as control and SCC samples were obtained 
from different individuals (32).
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A possible limitation of this study is the small patient group. However, based on the 
comprehensiveness of our sample sets, the high number of included HPV types and the 
unique study design, we believe the generated data provide valuable new information that 
is generalisable. Our study population was representative of SCC patients generally seen 
in the Townville area in terms of average age (70 versus 67 years) as the key risk factor for 
SCC in a high-risk population like Townsville, though it contained a higher proportion of 
males (80%) than seen overall (61%) (34).
In summary, this series of samples of SCC-patients show that perilesional skin is clearly 
different from normal skin with respect to betaPV infection, supporting the field change 
hypothesis for cutaneous SCC development. The contribution of betaPV to field cancerisa-
tion is unknown but might be related to its property to impair cellular defenses against 
UV-induced DNA damage (35;36). The clinical relevance, if any, of the difference in 
betaPV types is unknown. Since no specific types were identified in any of the particular 
biopsies that were not present in other samples, no obvious high-risk types emerged in this 
series. Possibly, the number of types or a combination of certain types increases the risk of 
developing a SCC (25;32). It is also possible that detection of more betaPV types represents 
higher viral loads accompanied by greater viral gene expression and an increased risk of 
SCC.
Similar analyses in larger datasets, ideally including measures of viral load, may help to 
elucidate the role of betaPV in cutaneous carcinogenesis, and to determine whether the 
betaPV status of eyebrow hairs is a sufficiently good marker of infection of the tumour field 
to warrant its continued use in epidemiological studies.
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abst ract
Betapapillomavirus (betaPV) DNA and seroresponses are highly prevalent in the general 
population and both are frequently used as infection markers in epidemiological studies to 
elucidate an association with cutaneous squamous-cell carcinoma (SCC). Little is known 
about the natural history of betaPV infection and the aspects of infection that drive antibody 
responses. To investigate the relation between these markers we assesed if the presence 
or persistence of betaPV DNA in eyebrow hairs and L1 antibodies of the same betaPV 
type co-occur more frequently than would be expected by chance in both a cross-sectional 
assessment and in a longitudinal study.
BetaPV DNA in plucked eyebrow hairs and L1 antibodies in serum were measured in 
416 participants of the Australian community-based Nambour Skin Cancer Study in 1996. 
Similar data were available for a subset of 148 participants in 2003. Observed co-occurence 
of betaPV DNA and antibodies was compared with expected values based on prevalence. A 
case-wise concordance index was used to calculate the overall concordance of the betaPV 
DNA and antibodies of the same type.
No significant associations were found between the presence or persistence of betaPV DNA 
and antibody responses. Age and sex of the host did not influence the association, nor 
did SCC-status or a history of sunburns. We conclude that betaPV antibody responses in 
adults are not primarily driven by betaPV infection as measured in eyebrow hairs. Other 
factors, such as viral load, possibly play a more pivotal role in induction of detectable 
seroresponses.
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in t roduct ion
Human papillomaviruses of the beta-genus (betaPV) are non-enveloped cutanotropic DNA 
viruses that may be associated with the development of cutaneous squamous-cell carcinoma 
(SCC) (1). So far 31 different betaPV types have been fully sequenced (2;3). 
Epidemiological studies have shown that betaPV DNA is frequently found in hair bulbs of 
eyebrows and body hairs (4), normal skin swabs (5) and biopsies from healthy people and 
transplant recipients without skin cancer (6), as well as in SCC tumor tissue (7-10). The 
presence of betaPV DNA has been associated with the presence of SCC-precursor lesions 
(actinic keratoses, AK) and SCC (11-14). Antibodies against the betaPV major capsid 
antigen L1 can be found in serum of healthy controls as well as patients with AK and SCC 
and have been associated with both tumor types in epidemiological studies (12;15;15-24).
Little is known about the association between betaPV DNA in hair follicles and serum 
antibodies. It may be expected that antibodies arise as a result of infection of the hair 
follicles with betaPV DNA, but the specific aspects of betaPV infection that drive antibody 
responses are currently unknown. For example, the location, load and persistence of infec-
tion, as well as inflammation at the site of infection may all be important in this respect 
(9;21).
Only two studies so far have investigated betaPV sero-prevalence among people with 
known betaPV DNA status (12;25). Struijk and co-workers reported a significantly higher 
prevalence of L1 seropositivity in those who were betaPV DNA positive in eyebrow hairs 
than in those in whom betaPV DNA was not detected (12;25). Andersson and co-workers 
reported that seropositivity was twice as common among people who had DNA detected 
for at least one betaPV type in a healthy skin or SCC biopsy, and that 20% of people 
with betaPV DNA were positive for L1 antibodies of the same type (25). In both studies, 
however, there was no statistical assessment of whether the associations found were higher 
than what would be expected on the basis of chance alone. 
In comparison with betaPV, there is substantially more knowledge about alphapapilloma-
viruses. For example for HPV16, L1 capsid antibodies are known to be a valid measure 
of lifetime HPV16 exposure and the association between HPV16 DNA in cervical biopies 
and capsid protein antibodies is high (26). Within a few months after the acquisition of 
viral DNA a serological response is evoked in 50% of infected women. The majority of 
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HPV DNA-positive women clear the infection within 12 months (27-29). In women with 
persistent presence of HPV DNA in samples taken at two different occasions, the percent-
age of seropositive women is higher than in women with HPV DNA diagnosed on a single 
occasion (30). Although the pathophysiology of betaPV seems very different to that of 
the high-risk viruses with mucosal tropism, these data raise the possibility that betaPV 
persistence might also be linked to a serological response.
To elucidate the role of betaPV infection measured as the presence of viral DNA in the 
development of betaPV L1 antibodies, we aimed to assess firstly if detection of betapapil-
lomavirus DNA in eyebrow hairs was associated with seropositivity for the same types 
in a cross-sectional assessment. Secondly, we evaluated to what extent persistent DNA 
infection determined seropositivity. Due to lack of information about long-term persistence 
of DNA, we measured betaPV DNA persistence from 1996 to 2003 on the assumption that 
this is indicative of infection prior to antibody formation. The study was performed in the 
context of an Australian longitudinal skin cancer study. 
mater ia l  and methods
study population and sample collection
Participants were an unselected subset of the study population of the Nambour Skin Cancer 
Study described in detail previously (31;32). Briefly, in 1986, 2095 of 3000 randomly 
selected residents of Nambour, a subtropical township in Australia (latitude 26°S), who 
were aged 20-69 years, participated in a skin cancer prevalence survey. From 1992 to 1996, 
1621 of these participants took part in a trial of sunscreen application and beta-carotene 
supplementation for the prevention of skin cancer. In 1996, 507 unselected participants 
took part in a sub-study aiming to understand the association between HPV and skin cancer 
(33). Ten eyebrow hairs were plucked from each participant and blood was drawn where 
possible. For the present study we used the data from 416 people for whom betaPV DNA 
and antibodies from 1996 were both available (herein called the ‘cross-sectional group’). 
To analyse the association between persistent betaPV DNA and seropositivity, we used data 
from 148 people of whom betaPV DNA and serum antibodies from 1996 and also from 
2003 were available (herein called the ‘longitudinal group’). Skin cancer follow-up took 
place until 31 December 2007. Ethical approval for all aspects of the study was obtained 
through the Bancroft Centre Human Research Ethics Committee, Queensland Institute of 
Medical Research. 
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dna isolation, pcr and hybridization
DNA from eyebrow hairs was isolated according to a method described previously(34). 
BetaPV detection and genotyping were performed using a reversed hybridisation assay as 
described by De Koning and collegues (35). All amplimers generated with the broad spec-
trum PCR were analysed with a reverse hybridization assay (RHA) that permitted specific 
detection and identification of 25 established betaPV genotypes of which the following 
were used: 5, 8, 9, 14, 15, 17,20, 21, 22, 23, 24, 36, 38, 47, 49, 75, 76, 80, 92, 93 and 96. 
The RHA was performed according to the manufacturer’s instructions (skin (beta) HPV 
prototype research assay; Diassay BV, Rijswijk, The Netherlands). 
multiplex serology
Serum samples were tested for the presence of antibodies to the major capsid antigen L1 
of HPV 5, 8, 9, 14, 15, 17, 20, 21, 22, 23, 24, 36, 38, 47, 49, 75, 76, 80, 92, 93 and 
96 by multiplex serology. This is an antibody detection method based on a glutathione 
S-transferase capture ELISA, in combination with fluorescent bead technology (17;25;36). 
Positive serology cut-offs were standardised at 200 MFI (Mean Fluorescence Intensity). 
statist ical analyses
We calculated the prevalence of betaPV DNA and antibodies for any betaPV type overall 
and for each of the 21 genotypes tested both for DNA and antibodies. To test for significant 
differences between DNA and antibody prevalence of the same genotype we used McNe-
mar tests. Persistent DNA was defined as having betaPV DNA detected for the same type 
in 1996 and in 2003, as we described previously (13).
To assess associations between betaPV DNA and antibody detection in the cross-sectional 
group, we calculated case-wise concordance, defined as the conditional probability that 
someone is positive for antibodies from a specific betaPV type given that s/he is betaPV 
DNA positive for that same type. It was estimated as the ratio of the number of concordant 
people (positive for DNA and antibodies for the same betaPV type) to the total of concordant 
and discordant (did not have betaPV DNA and antibodies for the same type) people. It can 
be interpreted similarly to a kappa statistic. The standard error and 95% confidence interval 
were estimated according to methods documented by Huang and Tai (37). We estimated 
concordance separately for each betaPV type and then calculated a pooled estimate across 
all types. To determine whether having persistent betaPV DNA was associated with the 
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presence of antibodies, we also calculated case-wise concordance between betaPV DNA 
persistence and the presence of antibodies in both 1996 and 2003.
For each betaPV type we multiplied the proportion of participants positive for antibodies 
by the proportion positive for DNA to calculate the proportion that would be expected 
to be concordant for both measures purely by chance. To calculate the number of people 
that would be expected to be concordant for at least one type, these 21 proportions were 
summed and the product multiplied by the number of people measured. We compared 
the number observed with that expected, using a Chi-squared test to determine statisti-
cal significance. Because age, sunburns and SCC-status have all been shown to influence 
betaPV-seroreactivity (17;20;21;24), stratified analyses were performed for sex, age below 
and above the mean age, lifetime sunburns (0, 1-4, 5+) and SCC (detected 1986-1996). 
The same approaches were used to determine associations between persistent DNA and 
antibodies detected in 1996 and 2003 (n=148). Because seroprevalence was very stable 
(overall, 89% of people remained either seropositive or seronegative) and analyses with 
2003 antibodies showed the same results as with the 1996 antibodies, we present in this 
paper only the results of the 1996 betaPV antibodies. Statistical analyses were performed 
with SAS 9.1.
resul ts
population characterist ics
The mean age of the 416 participants in the HPV DNA data and L1 antibody data from 1996 
(the cross-sectional group) was 51 years, and 50% were male. In total 60 people (14%) had 
never had a painful sunburn, 184 people (44%) had experienced 1 to 4 painful sunburns in 
their life and 172 people (41%) had had 5 or more painful sunburns. Eighteen people (4%) 
were newly diagnosed with a SCC between 1986 and 1996.
The mean age of the 148 people for whom HPV DNA data was available from both 1996 
and 2003 (the longitudinal subgroup) was 50 years, and 47% were male. Painful sunburns 
had the same distribution as in the whole cohort and 4 (3%) people in this group developed 
a SCC between 1986 and 1996.
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association between betapv dna presence and l1 antibodies 
(cross-sectional group)
The prevalence of betaPV DNA in the cross-sectional group was 74%, with 53% of people 
being positive for more than one type (Table 1). There were 288 people (69%) with betaPV 
antibodies and 51% had antibodies against more than one type. The prevalence of indi-
vidual types ranged from 0 to 23% for DNA, and 0 to 33% for antibodies.
Table 1: Prevalence of betaPV DNA in eyebrow hairs and betaPV antibodies, overall and per 
betaPV type
 cross-sectional group (n=416) longitudinal group (n=148)
 
1996
DNA
1996
antibodies
1996
DNA
1996
antibodies
1996-2003
persistent DNA
 N (%) N (%) N (%) N (%) N (%)
Overall 308 (74) 288 (69) 107 (72) 95 (64) 73 (49)
      
HPV5 46 (11) 36 (9) 17 (11) 14 (9) 11 (7)
HPV8 44 (11) 137 (33)* 17 (11) 47 (32)* 5 (3)
HPV9 52 (13) 68 (16) 17 (11) 29 (20)* 11 (7)
HPV14 20 (5) 4 (1)† 3 (2) 2 (1) 1 (1)
HPV15 73 (18) 102 (25)* 22 (15) 38 (26)* 7 (5)
HPV17 70 (17) 118 (28)* 26 (18) 41 (28)* 10 (7)
HPV20 42 (10) 47 (11) 16 (11) 16 (11) 7 (5)
HPV21 10 (2) 86 (21)* 5 (3) 35 (24)* 2 (1)
HPV22 35 (8) 51 (12) 10 (7) 17 (11) 4 (3)
HPV23 94 (23) 62 (15)† 27 (18) 21 (14) 10 (7)
HPV24 69 (17) 68 (16) 21 (14) 25 (17) 12 (8)
HPV36 73 (18) 53 (13)† 22 (15) 20 (14) 11 (7)
HPV38 83 (20) 139 (33)* 27 (18) 49 (33)* 15 (10)
HPV47 0 (0) 56 (13)* 0 (0) 21 (14)* 0 (0)
HPV49 53 (13) 104 (25)* 19 (13) 33 (22)* 11 (7)
HPV75 11 (3) 64 (15)* 3 (2) 23 (16)* 0 (0)
HPV76 35 (8) 63 (15)* 8 (5) 24 (16)* 3 (2)
HPV80 42 (10) 78 (19)* 13 (9) 25 (17)* 9 (6)
HPV92 27 (6) 56 (13)* 9 (6) 21 (14)* 7 (5)
HPV93 70 (17) 13 (3)† 27 (18) 7 (5)† 14 (9)
HPV96 33 (8) 79 (19)* 12 (8) 27 (18)* 10 (7)
No of types      
0 108 (26) 128 (31) 41 (28) 53 (36) 75 (51)
1 86 (21) 76 (18) 35 (24) 22 (15) 31 (21)
2 66 (16) 44 (11) 20 (14) 17 (11) 20 (14)
3+ 156 (37) 168 (40) 52 (34) 56 (38) 22 (14)
* Significant difference in prevalence where antibody>DNA
†Significant difference in prevalence where DNA>antibody
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We found no association between being betaPV DNA and antibody positive. Among the 
308 people with detectable betaPV DNA in 1996, 217 people (70%) had betaPV antibodies, 
while among the 108 people without betaPV DNA, 66% had betaPV antibodies detected 
(p=0.30). For 12 of the 21 betaPV types the antibody prevalence was significantly higher 
than DNA prevalence (p <0.05), while for 4 of the 21 types the DNA prevalence was 
significantly higher than for antibodies (Table 1). Although no person in the cohort had 
HPV47 DNA detected, 56 people (18%) had antibodies against HPV47.
The pooled case-wise concordance index between betaPV DNA and antibodies for the 
cross-sectional group was 0.18 (95% CI 0.16-0.20). Examining individual betaPV type 
concordance, we found all case-wise concordance indices to be below 0.28 (Table 2). Of 
the 217 people with both betaPV DNA and L1 antibodies, 114 people (53%) were posi-
tive for at least one betaPV DNA and antibody of the same type, whereas 140 (65%) was 
expected on the basis of chance (p=0.15). Of the 308 people with at least one betaPV 
DNA type, 114 people (37%) were positive for at least one of the corresponding betaPV 
antibodies, compared with 138 expected (p=0.045) (Table 3). 
Table 2: Type-specific concordance between betaPV DNA and antibodies measured in 1996 in the 
cross-sectional group (N=416).
 
N (%) DNA 
positive
N (%) of DNA+ 
who are AB +
N (%) DNA 
negative
N (%) DNA - 
who are AB +
case-wise
concordance 
index
HPV5 46 (11) 10 (22) 370 (89) 26 (7) 0.24
HPV8 44 (11) 18 (41) 372 (89) 119 (32) 0.20
HPV9 52 (13) 7 (13) 364 (88) 61 (17) 0.12
HPV14 20 (5) 0 (0) 396 (95) 4 (1) 0.00
HPV15 73 (18) 20 (27) 343 (82) 82 (24) 0.23
HPV17 70 (17) 25 (36) 346 (83) 93 (27) 0.27
HPV20 42 (10) 11 (26) 374 (90) 36 (10) 0.25
HPV21 10 (2) 2 (20) 406 (98) 84 (21) 0.04
HPV22 35 (8) 7 (20) 381 (92) 44 (12) 0.16
HPV23 94 (23) 14 (15) 322 (77) 48 (15) 0.18
HPV24 69 (17) 10 (14) 347 (83) 58 (17) 0.15
HPV36 73 (18) 14 (19) 343 (82) 39 (11) 0.22
HPV38 83 (20) 31 (37) 333 (80) 108 (32) 0.28
HPV47 0 (0) 0 (0) 416 (100) 56 (13) 0.00
HPV49 53 (13) 17 (32) 363 (87) 87 (24) 0.22
HPV75 11 (3) 3 (27) 405 (97) 61 (15) 0.20
HPV76 35 (8) 6 (17) 381 (92) 57 (15) 0.12
HPV80 42 (10) 12 (28) 373 (90) 66 (18) 0.20
HPV92 27 (6) 7 (26) 389 (94) 49 (13) 0.17
HPV93 70 (17) 3 (4) 346 (83) 10 (3) 0.07
HPV96 33 (8) 5 (15) 383 (92) 74 (19) 0.09
chapter 4   61
When we stratified by age (below 50 years and 50 years and over) no significant differences 
were found in the proportion of people who were betaPV DNA and antibody concordant 
for at least one type (p=0.62). In those aged below 50 years, 42 people were concordant 
compared with 52 expected (p=0.15), and in those older than 50 years, 72 were observed 
and 86 expected (p=0.14) (Table 3).
Stratification by SCC-status did not show any significant differences in the proportion of 
people that were DNA-antibody concordant (p=0.70). In the group with a SCC detected, 
9 people were concordant compared with 10 expected (p=0.71), and in the group without 
SCC 106 were observed and 127 expected (p=0.09). There was also no difference accord-
ing to sex or number of lifetime sunburns (Table 3).
association between betapv dna persistence and l1 antibodies 
(longitudinal group) 
The prevalence of betaPV DNA at baseline was 72%, with 48% of people being positive 
for more than one type (Table 1). Ninety-five persons (64%) had betaPV antibodies at 
baseline and 49% had antibodies against more than one type. The prevalence of antibodies 
for individual betaPV types ranged from 0 to 18% for DNA and 0 to 33% for antibodies. 73 
Table 3: Number of betaPV types observed (OBS) and expected (EXP) to be in common for DNA 
and antibodies for all people with DNA for at least one betaPV type
Cross-sectional group (n=416) Longitudinal group (n=148)
 betaPV prevalence and antibodies betaPV persistence and antibodies
 n
OBS 
N (%)
EXP 
N (%) p-value n
OBS 
N (%)
EXP 
N (%) p-value
All DNA+ participants 308 114 (37) 138 (45) 0.05 73 28 (38) 25 (34) 0.61
         
Age < 50 years 119 42 (35) 52 (45) 0.15 33 13 (39) 12 (33) 0.61
Age ≥ 50 years 189 72 (38) 86 (46) 0.14 40 15 (38) 12 (30) 0.48
         
Males 157 67 (43) 79 (51) 0.14 36 14 (39) 13 (36) 0.81
Females 151 48 (32) 60 (40) 0.15 37 14 (38) 12 (32) 0.63
         
no sunburns 50 18 (36) 22 (44) 0.41 9 4 (44) 2 (22) 0.32
1-4 sunburns 139 56 (40) 65 (47) 0.28 37 15 (41) 15 (41) 1.00
5+ sunburns 116 41 (35) 51 (44) 0.18 27 9 (33) 10 (37) 0.58
         
no SCC 293 106 (36) 127 (43) 0.09 70 26 (37) 23 (33) 0.60
SCC 15 9 (60) 10 (67) 0.71 3 2 (66) 1 (33) 0.40
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people (49%) had persistent DNA detected for at least one betaPV type in both 1996 and 
2003 (Table 1). 
The pooled concordance index describing the association between persistent DNA and 
antibodies was 0.13 (95% CI -0.005-0.27) and all individual case-wise concordance indices 
were below 0.32 (Table 4). Twenty-eight participants (38%) who had persistent betaPV 
DNA also had L1 antibodies detected in 1996 for at least one betaPV type, which was not 
significantly different from the number expected to occur by chance (N=25, p=0.61) (Table 
3). There were no significant differences in relation to age, sex, history of sunburns or 
SCC-status among study participants (Table 3). 
Table 4: Type-specific concordance between DNA persistence and antibodies in the longitudinal 
group (N=148). 
N (%) 
persistence
positive
N (%) of 
persistent+ who 
are 1996 AB +
N (%) 
persistence 
negative
N (%) of 
persistent- who 
are 1996 AB +
case-wise
concordance 
index
HPV5 11 (7) 4 (36) 137 (93) 10 (7) 0.32
HPV8 5 (3) 1 (20) 143 (97) 46 (32) 0.04
HPV9 11 (7) 3 (27) 137 (93) 26 (19) 0.15
HPV14 1 (1) 0 (0) 147 (99) 2 (1) 0.00
HPV15 7 (5) 1 (15) 141 (95) 37 (26) 0.04
HPV17 10 (7) 4 (40) 138 (93) 37 (26) 0.16
HPV20 7 (5) 2 (29) 141 (95) 14 (10) 0.17
HPV21 2 (1) 1 (50) 146 (99) 34 (23) 0.05
HPV22 4 (3) 1 (25) 144 (97) 16 (11) 0.10
HPV23 10 (7) 3 (30) 138 (93) 18 (13) 0.19
HPV24 12 (8) 4 (33) 136 (92) 21 (15) 0.22
HPV36 11 (7) 2 (18) 137 (93) 18 (13) 0.13
HPV38 15 (10) 7 (47) 133 (90) 42 (32) 0.22
HPV47 0 (0) 0(0) 148 (100) 21 (14) 0.00
HPV49 11 (7) 4 (36) 137 (93) 29 (21) 0.18
HPV75 0 (0) 0 (0) 148 (100) 23 (16) 0.00
HPV76 3 (2) 0 (0) 145 (98) 24 (17) 0.00
HPV80 9 (6) 4 (44) 139 (94) 21 (15) 0.24
HPV92 7 (5) 2 (29) 141 (95) 19 (13) 0.14
HPV93 14 (9) 1 (7) 134 (91) 6 (4) 0.10
HPV96 10 (7) 2 (20) 138 (93) 25 (18) 0.11
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d iscuss ion
This study assessed the associations between both prevalence and persistence of betaPV 
DNA, and L1 antibodies, and found that neither DNA measure was predictive of antibody 
detection.
The overall betaPV DNA prevalence of 74% we measured at baseline was lower than has 
been reported previously in an Australian population (91%) (6). BetaPV detection has been 
shown to increase with age (6), so this difference is probably due to the younger age of 
our participants. The overall seroprevalence of 69% is higher than previously reported for 
Australia (17). As betaPV seropositivity increases with age (17;38), the relatively high 
seroprevalence in our study is not due to age and remains unexplained. 
We found antibodies to be very stable over 8 years, with only 16 people (11%) changing 
their overall betaPV serology status between 1996 and 2003, and they had MFI values very 
close to the cut-off. We analysed our data using antibody status in 2003 and, due to the 
stability of these antibodies, found no difference in the results.
HPV47 DNA was not found in eyebrow hairs of any of the participants but 13% were 
seropositive for HPV47. Although sero cross reactivity, possibly with unknown betaPV 
types, cannot be excluded, it could be possible that the reference HPV47 type represents 
a regional variant (39). So far HPV47 DNA has only been found in an ongoing study in 
organ transplant patients using this method (M.N.C de Koning, unpublished observation), 
and other betaPV typing methods targeting different genomic regions of HPV47 have also 
detected this type (40;41). However, removal of HPV47 from the analyses did not change 
the results of this study, because the proportions of DNA- antibody concordance as well as 
the case-wise concordance remained unaffected. 
Neither the presence nor persistence of betaPV in eyebrow hairs was associated with the 
detection of L1 antibodies. All type-specific and pooled concordance indices were low and 
there were no consistent differences in the number of people expected to be concordant and 
the number observed. Stratification by age, sex, history of sunburns or SCC did not alter 
these findings. 
Two other studies have addressed the relation between betaPV DNA and antibodies. One 
study found a significantly higher prevalence of L1 positivity in those who were betaPV 
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DNA positive than in those in whom betaPV DNA was not detected (12). Of the 37 par-
ticipants in that study with both betaPV DNA and L1 antibodies, 32% were positive for the 
same type (12). However we would expect some people to be positive by chance alone, and 
without knowledge of this expected number, results are difficult to interpret. We found that 
53% of people who were DNA and antibody positive had at least one virus type where both 
measures were positive, but this was not higher than expected based on the prevalence of 
DNA and antibodies. A second study found that seropositivity was twice as common among 
people who had DNA detected for at least one betaPV type in a healthy skin or an SCC on 
biopsy, and that 20% of people with betaPV DNA were positive for L1 antibodies of the 
same type (25), but again there was no reference to an expected value. Although we found 
that 37% of people with betaPV DNA in eyebrow hairs were antibody positive for at least 
one type detected, this was not higher than expected by chance. 
There are several possible explanations for our observed lack of association between 
betaPV DNA and L1 antibodies. It may be that the presence and/or persistence of betaPV 
DNA we measured was not indicative of infection many years many years prior to 1996 
and that the antibody response was provoked earlier in life when the DNA was not present. 
However, a previous study showed that antibody responses against betaPV types are rare in 
childhood and have their peak prevalence between 40 and 60 years for women and 50 and 
70 years for men suggesting that antibodies arise at a time more proximal to our measure 
of infection (38). Secondly it is possible that antibodies are detected for multiple types due 
to cross-reactivity, without there being infection of the skin with those types, and true type-
specific seroresponses may be lower than measured. The high multiplicity of L1 antibodies 
and the significantly higher prevalence of antibody positivity than betaPV DNA positivity 
for 12 types may support this hypothesis. Alternatively, betaPV antibody responses may be 
associated with the betaPV load rather than simply with presence or absence of viral DNA. 
Loads of betaPV shown as the number of HPV copies per infected cell are known to be 
much lower when compared with the alpapapillomavirus types (9), but increases in load 
might be important in evoking an antibody response.
BetaPV DNA detection in eyebrow hairs has been used as a convenient marker of infection 
in epidemiological studies, but it is unclear to what extent this is indicative of pathologi-
cally relevant skin infection. Although we and others have shown some association between 
betaPV DNA found in eyebrow hairs and in biopsies of cutaneous SCC and the perilesional 
skin (7;8;10), the prevalence in eyebrow hairs is substantially higher than in other tissues. 
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Thus it seems likely that a high proportion of infections in eyebrow hairs do not evoke an 
antibody response.
As the induction of immune response often requires additional signals, inflammation 
accompanying betaPV infections might be an important factor in evoking seroresponses. 
Favre and colleagues showed the induction of HPV5 seroresponses upon second degree 
burns of the skin, as well as in patients with autoimmune bullous diseases and psoriasis, 
all diseases with prominent inflammation (21). BetaPV infections as detected in eyebrow 
hairs are not known to be accompanied by inflammation. However, if eyebrow hairs are 
indicative of infection at other sites, we might expect that our association between betaPV 
and antibody detection would be altered by a history of sunburns or SCC. We did not find 
an effect however, of previous sunburns or SCC on the association between betaPV DNA 
and L1 antibodies. Possibly, inflammation in the context of most SCC and AK is small 
compared with those conditions examined by Favre et al (21).
In conclusion, we did not find a meaningful association between betaPV DNA presence 
or persistence in eyebrow hairs and betaPV-L1 antibodies in serum. This lack of associa-
tion highlights the need to better understand the natural history of betaPV infection, and 
the ways in which infection induces an immune response, before associations between 
measures of betaPV infection and disease can be elucidated. 
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abst ract
Human papillomaviruses from the beta genus (betaPV) are a possible cause of cutane-
ous squamous-cell carcinoma (SCC). We assessed the extent to which betaPV infections 
persisted long-term in a subtropical Australian community and whether betaPV persistence 
is positively associated with actinic keratoses (AK), precursor for SCC.
Eyebrow hairs were collected from 171 participants of the community-based Nambour 
Skin Cancer Study in 1996 and 2003. Hair samples were tested for the presence of DNA 
from 25 different betaPV types and assessed in relation to AK presence in 2007.
In 1996 a total of 413 betaPV infections were found in 73% of participants, rising to 490 
infections among 85% in 2003. Of the total betaPV infections detected, 211 (30%) were 
found to persist. Age was significantly associated with betaPV persistence: those over 60 
years had 1.5 fold (95% CI 1.1-1.9) increased risk of type-specific viral-persistence than 
those under 40. After accounting for AKs at baseline, persistence of betaPV DNA resulted 
in a 1.4 fold (95% CI 1.0-1.9) increase in risk of having AKs on the face in 2007.
In conclusion, persistent betaPV infections in this population were associated with an 
increased occurrence of AK. Additional studies are needed to determine the possible asso-
ciation of betaPV persistence with SCC.
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in t roduct ion 
Human papillomaviruses (HPV) have oncogenic capacities and persistent infection with a 
high-risk mucosal HPV type from the alpha genus causes the development of cervical can-
cer (1;2). HPV from the beta genus (betaPV) have cutaneous rather than mucosal tropism. 
They were first found to cause flat, wart-like lesions in epidermodysplasia verruciformis 
(EV) patients and so were formerly known as EV-types. Currently 25 betaPV-types have 
been fully sequenced (HPV5, 8, 9, 12, 14, 15, 17, 19-25, 36-38, 47, 49, 75, 76, 80, 92, 93 
and 96) (3), but many more new types can probably be added to this list based on partial 
sequences (4).
BetaPVs are detected frequently in actinic keratoses (AKs) and cutaneous squamous-cell 
carcinomas (SCCs), but have also been found in biopsies from normal skin, eyebrow hairs 
and skin swabs from people with and without skin cancer (5-7). A number of studies have 
shown statistically significant associations between markers of betaPV infection (viral 
DNA in eyebrow hairs or skin biopsies, and antibodies in serum) and SCC (8-12), but no 
betaPV types have been found to cause SCC in experimental systems.
There is limited knowledge about persistence of cutaneous betaPV infection over extended 
periods of time. Studies of betaPV persistence in eyebrow hairs so far have involved rela-
tively few participants followed over limited time periods (two to six years) (13;14), and no 
studies have examined betaPV persistence in relation to future occurrence of AK or SCC. 
Furthermore, most epidemiological studies have been cross-sectional (11;15), assessing 
both betaPV detection in an individual’s eyebrow hairs and their skin cancer status at the 
same point in time. 
One of the few cohorts available for estimation of the risk of skin cancer in regard to HPV 
infection has been the Nambour Skin Cancer Study cohort (16;17). Boxman and colleagues 
performed a cross-sectional study with 518 individuals sampled in 1996 and found a strong 
association between betaPV infection and AKs in men, but not women (17). McBride and 
colleagues studied the prevalence of AKs in 291 participants of the Nambour Skin Cancer 
Study 7 years after single measurement of betaPV DNA in eyebrow hairs. They found that 
betaPV-positivity was associated cross-sectionally with the presence of more than 10 AKs, 
especially in those over 60 years, those who had fair skin or those who had experienced 
high sun exposure (16). 
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In the present more detailed and longer-term study of the Nambour Skin Cancer Study 
cohort, we assessed the persistence of 25 different betaPV types in eyebrow hairs over an 
8-year period, and then examined the longitudinal association between betaPV persistence 
and the disease outcome, actinic keratoses, over a total period of 11 years.
mater ia ls  and methods
study population and sample collection
Participants comprised an unselected subset of the study population of the Nambour Skin 
Cancer Study (Figure), described in detail previously (18-20). Briefly, in 1986, 2095 of 
3000 randomly selected residents aged 20-69 years, from Nambour, a subtropical township 
in Australia (latitude 26°S) participated in a skin cancer prevalence survey. From 1992 
to 1996, 1621 of these participants then took part in a trial of sunscreen application and 
beta-carotene supplementation for the prevention of skin cancer, and follow-up continued 
until 2007.
In 1996, 507 participants took part in a sub-study aiming to understand the association 
between HPV and skin cancer (17). Ten eyebrow hairs were plucked from each participant 
and processed as described below. In 2003, 291 of these 507 who were still actively partici-
pating in the follow-up of the Nambour Skin Study took part in a second phase of the HPV 
study when eyebrow hairs were plucked again (16). At baseline and in 2003 standardized 
questionnaires were used to elicit information about skin type, and sun exposure.
In 1992, 1994 and 1996 specialist dermatologists conducted full-body skin examinations of 
study participants and documented the degree of telangiectasia and nuchal elastosis and the 
number of AKs on each anatomical site. A proportion of participants were fully examined 
for actinic keratoses again in 2007 (Figure).
Ethical approval for all aspects of the study was obtained through Bancroft Centre Ethics 
Committee, Queensland Institute of Medical Research.
dna isolation, pcr and hybridization
DNA from eyebrow hairs collected in 1996 was isolated according to a method described 
previously (21). The 2003 eyebrow hairs were treated using the QIAamp DNA mini kit 
(Qiagen). Briefly, hairs were pre-treated overnight with proteinase K solution according 
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to the manufacturer’s instructions. After lysis with 200 μl AL buffer, half of the volume 
was stored at -70oC, whilst the other half was processed according to the manufacturer’s 
instructions.
BetaPV detection and genotyping of 1996 and 2003 samples was performed using a 
reversed hybridization assay as described previously (22). Briefly, PM-PCR was performed 
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Figure. Nambour Skin Cancer Study flow diagram, December 1986 to August 2007. (adapted  from 
(16). 
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171 eyebrow hair samples 
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138 people available for skin 
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Figure. Nambour Skin Cancer Study flow diagram, December 1986 to August 2007. (adapted from
(16).
76  chapter 5 
in a final reaction volume of 50 μl, containing 10 μl of the isolated DNA, 2.5 mM MgCl2, 
1x GeneAmp PCR buffer II, 0.2 deoxynucleotide triphosphates, 1.5 U AmpliTaq Gold 
DNA polymerase and 10 μl of the PM primer mix. The PCR was performed by a 9 min pre-
heating step at 94oC, followed by 35 cycles of amplification comprising 30 s at 94oC, 45 s at 
52oC, and 45 s at 72 oC. The PCR was ended by a final elongation step at 5 min at 72 oC. As 
the positive PCR control, a betaPV plasmid clone was included at an amount approximately 
100 times the limit of detection of the assay. All positive controls were detected. Each tenth 
sample was a negative isolation control that was processed parallel to the other samples of 
which 12 percent was positive with no specific betaPV type standing out.
 
All amplimers were subsequently analyzed with a reverse hybridization assay (RHA) that 
permitted specific detection and identification of the 25 established betaPV genotypes (i.e., 
5, 8, 9, 12, 14, 15, 17, 19-25, 36-38, 47, 49, 75, 76, 80, 92, 93 and 96). The RHA was 
performed according to the manufacturer’s instructions (RHA Kit Skin (beta) HPV, Diassay 
BV).
statist ical analyses 
Chi square tests were used to analyze univariate associations. To examine factors associ-
ated with persistence, and the association between betaPV infection/persistence and AKs, 
binomial models were used to compute relative risks (RRs) and 95% confidence intervals 
(CI). A range of possible confounding factors were explored but none of the following: skin 
type, occupational sun exposure, sunburns, smoking, use of sunglasses and randomized 
sunscreen /beta-carotene interventions, altered the effect estimates and therefore were not 
included in the models. The final model describing associations with betaPV detection 
over time was adjusted for age; the final models for assessing association with AKs were 
adjusted for age, sex and the presence of AK at baseline. Statistical analyses were per-
formed in SAS 9.1. 
resul ts
baseline
BetaPV DNA detection and typing information for the participants from 2003 was available 
for 171 of the 507 participants (34%) whose data were first analyzed in 1996, and these 
therefore formed the basis of this study. The characteristics of the 171 participants, whose 
mean age in 1996 was 50 years, were not significantly different to the remainder seen 
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at baseline (data not shown). Half of the participants reported their skin type as fair and 
most had mainly indoors occupations. On dermatologic examination in 1996, moderate to 
extensive photo ageing of the skin of the neck (nuchal elastosis) was prevalent in at least 
50% of participants.40% of participants had AK present at baseline, ranging from 23% 
in the group under 40 to 61% in the older than 60 years group (Table 1). Of the 171, 138 
(81%) were still active in the study in 2007 and underwent the final skin examination.
betapv detection and typing
Of the 25 who were betaPV negative in 2003, 11 (6% of all participants) were also betaPV 
negative in 1996. Of the 171 subjects whose betaPV was measured, 11 (6%) were betaPV 
negative in 1996 and 2003. In 1996, 47 of 171 participants (27%) had no betaPV DNA 
Table 1: Baseline characteristics of (N=171) participants of the Nambour Skin Cancer study 
followed-up in 2003. 
 <40 years in 1996 40-60 years in 1996 >60 years in 1996
 N (%) N (%) N (%)
Sex    
male 27 (68) 44 (45) 12 (36)
female 13 (32) 54 (55) 21 (64)
    
skin color (self-reported)    
medium/olive 25 (63) 51 (52) 12 (36)
fair 15 (38) 47 (48) 21 (64)
    
occupational sun exposure    
mainly indoors 18 (45) 49 (50) 14 (42)
both indoor and outdoor 10 (25) 35 (36) 12 (36)
mainly outdoors 12 (30) 14 (14) 7 (21)
    
number of lifetime sunburns    
0 3 (8) 11 (11) 6 (18)
1-4 7 (18) 50 (51) 17 (52)
>5 30 (75) 37 (38) 10 (30)
    
nuchal elastosis    
limited 17 (47) 22 (23) 0 (0)
moderate 18 (50) 59 (62) 20 (54)
extensive 1 (3) 14 (15) 17 (46)
    
telangectasia face    
low 12 (30) 15 (15) 6 (18)
moderate 18 (45) 55 (56) 20 (61)
high 10 (25) 28 (29) 7 (21)
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detected and were therefore deemed to be betaPV negative. The 124 participants who were 
betaPV positive (73%) had between one and 12 different types detected (median 2), with 
100 people (81% of those positive) having multiple betaPV types (Table 2). 
In 2003, betaPV was detected in 146 of 171 participants (85%) and the median number of 
detections was 2 (range 1-14). Of those positive, 109 (75%) had more than one virus type 
detected. The total number of betaPV type-specific detections in all 171 participants in 
Table 2: Detection of betaPV DNA per type in eyebrow hairs of 171 participants of the Nambour 
Skin Cancer Study in 1996 and 2003
 1996, N (%) 2003, N (%) 1996 and 2003, N (%)
proportion 
persistent
Any betaPV type 124 (73) 146 (85) 83 (49)  
     
Total no. of infections 413 490 211* (30)  
     
HPV5 20 (12) 26 (15) 14 (8) 0,70
HPV8 23 (13) 23 (13) 10 (6) 0,43
HPV9 19 (11) 27 (16) 13 (8) 0,68
HPV12 13 (8) 15 (9) 7 (4) 0,54
HPV14 3 (2) 5 (3) 1 (1) 0,33
HPV15 26 (15) 25 (15) 8 (5) 0,31
HPV17 30 (18) 41 (24) 11 (6) 0,37
HPV19 10 (6) 17 (10) 5 (3) 0,50
HPV20 17 (10) 18 (11) 7 (4) 0,41
HPV21 5 (3) 5 (3) 2 (1) 0,40
HPV22 10 (6) 5 (3) 4 (2) 0,40
HPV23 32 (19) 33 (19) 12 (7) 0,38
HPV24 26 (15) 32 (19) 15 (9) 0,58
HPV25 6 (4) 4 (2) 3 (2) 0,50
HPV36 26 (15) 29 (17) 14 (8) 0,54
HPV37 9 (5) 12 (7) 5 (3) 0,56
HPV38 31 (18) 44 (26) 19 (11) 0,61
HPV47 0 (0) 0 (0) 0 (0) 0,00
HPV49 23 (13) 22 (13) 12 (7) 0,52
HPV75 3 (2) 4 (2) 0 (0) 0,00
HPV76 11 (6) 11 (6) 4 (2) 0,36
HPV80 17 (10) 31 (18) 12 (7) 0,71
HPV92 10 (6) 14 (8) 8 (5) 0,80
HPV93 30 (18) 28 (16) 15 (9) 0,50
HPV96 13 (8) 19 (11) 10 (6) 0,77
*The total number of betaPV type-specific infections detected (692) was calculated by adding up 
the total numbers of betaPV infections in 1996 (413) and 2003 (490) minus the total number of 
infections that were detected at both time-points (211).
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1996 was 413. Of these, 211 were also detected in 2003 (Table 2) and 202 were no longer 
detectable. In 2003, 279 viruses were detected which had not been found in 1996.
The most prevalent types in 1996 were HPV23 (19%), 17 (18%), 38 (18%) and 93 (18%). 
HPV47 was not found in any samples from 1996 or 2003. The types detected most fre-
quently in 2003 were HPV38 (26%), 17 (24%), 23 (19%) and 24 (19%) (Table 2), and for 
the persistent types HPV38 (11%), HPV24 (9%) and HPV93 (9%) were among the most 
prevalent types. HPV17, with prevalences of 18% and 24% in 1996 and 2003 respectively, 
was detected on both occasions in only 6% of participants. HPV-types 92, 96, 80, 5 and 9 
had the highest probabilities of persistence (Table 2).
Type-specific detection of betaPV DNA in 1996 and 2003, was seen in 83 of 171 (49%) 
of participants. Of these, 32 (39%) had one type persisting and 51 (61%) more than one 
(range 2-11).
The presence of betaPV DNA in 1996 and type-specific persistence both increased with 
age, with those over 60 having a 1.5 fold (95% CI 1.1-1.9) increased risk to have betaPV 
DNA detected in 1996 and a 1.6 fold (95% 1.0-2.8) increased risk to have at least one per-
sistent betaPV type as those under 40. Sex, skin type, occupational sun exposure, number 
of lifetime sunburns, use of sunglasses, elastosis of the neck and telangiectasia of the face 
were not associated with the presence of betaPV DNA in 1996, nor with persistence in 
2003 (Table 3). No interaction was observed between betaPV persistence and traditional 
risk factors for AK, although with the modest sample size the power to detect interactions 
was inadequate.
actinic keratoses
In 2007, 76 of 138 participants (55%) who underwent a skin examination had at least one 
actinic keratosis on the head and neck, and 94 of the 138 participants (68%) had at least one 
AK on the whole body. Twenty-seven of 138 participants (20%) had more than 10 AKs on 
the whole body. The presence of AKs in 2007 was associated with being aged over 60 years 
(RR 1.7 95% CI 1.2-2.4), male sex (RR 1.4, 95% CI 1.1-1.8), with the presence of AK at 
baseline (RR 1.9, 95% CI 1.5-2.5), having moderate (RR 1.8, 95% CI 1.1-2.9) or extensive 
(RR 2.4, 95% CI 1.5-3.8) solar elastosis of the neck, and high degree of telangiectasia of 
the face (RR 1.5, 95% CI 1.0-2.3).
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Table 4 shows the associations between actinic keratoses diagnosed in 2007 and the pres-
ence of betaPV DNA in 1996, 2003 and at both time points, adjusted for age, sex and AK 
diagnosed at baseline. Having betaPV detected at a single time point (in either 1996 or 
2003) was not associated with AK in 2007. BetaPV type-specific persistence however, was 
associated with AKs on head and neck (RR 1.4, 95% CI 1.0-1.9). When we repeated the 
analyses with only the 77 AK-free people at baseline the results were essentially identical, 
although with slightly wider confidence intervals. Associations between AKs diagnosed 
Table 3: BetaPV detection in 1996, 2003 and at both time points in relation to participants 
characteristics (RR adjusted for age).
 1996 (N=171) 2003 (N=171) 1996 and 2003 (N=171)
 
betaPV-
positive, 
N (%)
RR 
(95% CI)
betaPV- 
pos 
itive,N 
(%)
RR 
(95% CI)
betaPV-
positive, 
N (%)
RR 
(95% CI)
Age, y       
<40 25 (63) 1.0 33 (83) 1.0 14 (35) 1.0 
40-60 69 (70) 1.1 (0.9-1.5) 83 (85) 1.0 (0.9-1.2) 50 (51) 1.5 (0.9-2.3)
>60 30 (91) 1.5 (1.1-1.9) 30 (91) 1.1 (0.9-1.3) 19 (58) 1.6 (1.0-2.8)
Sex       
female 65 (74) 1.0 76 (86) 1.0 43 (49) 1.0 
male 59 (71) 1.0 (0.8-1.2) 70 (84) 1.0 (0.9-1.1) 40 (48) 0.9 (0.7-1.3)
Skin colour       
fair 65 (74)  1.0 72 (82) 1.0 46 (52) 1.0 
medium/olive 59 (71) 1.1 (0.9-1.3) 74 (89) 0.9 (0.8-1.1) 37 (45) 1.3 (0.9-1.7)
Occupational sun exposure  
mainly indoors 27 (82)  1.0 29 (94) 1.0 18 (55)  1.0 
both indoor and 
outdoor 40 (70) 0.9 (0.8-1.1) 50 (88) 1.0 (0.8-1.1) 25 (44) 0.8 (0.5-1.1)
mainly outdoors 57 (70) 0.9 (0.8-1.1) 67 (83) 0.9 (0.8-1.1) 40 (49) 0.9 (0.6-1.3)
Sunglasses       
never 20 (80)  1.0 21 (84) 1.0 11 (44)  1.0 
2-4 hours/day 40 (74) 1.0 (0.8-1.2) 49 (91) 1.1 (0.9-1.3) 30 (56) 1.4 (0.8-2.2)
5+ hours/day 63 (69) 1.0 (0.8-1.2) 75 (82) 1.0 (0.8-1.2) 42 (51) 1.2 (0.7-1.9)
Number of lifetime sunburns  
0 16 (80)  1.0 17 (85) 1.0 10 (50)  1.0 
1-4 58 (78) 1.0 (0.8-1.3) 64 (86) 1.0 (0.8-1.3) 41 (55) 1.0 (0.6-1.7)
>5 50 (65) 0.9 (0.7-1.2) 65 (84) 1.0 (0.8-1.3) 32 (42) 0.8 (0.5-1.4)
Nuchal elastosis 
limited 24 (67) 1.0 28 (78) 1.0 12 (33)  1.0 
moderate 67 (71) 0.9 (0.7-1.1) 87 (92) 1.1 (0.9-1.3) 50 (53) 1.4 (0.8-2.3)
extensive 30 (81) 1.0 (0.8-1.3) 29 (76) 0.9 (0.7-1.2) 20 (54) 1.3 (0.7-2.4)
Telangectasia face 
low 24 (73) 1.0 27 (81) 1.0 16 (48)  1.0 
medium 66 (71) 0.9 (0.8-1.2) 80 (86) 1.0 (0.8-1.2) 45 (54) 0.9 (0.6-1.4)
high 34 (77) 1.0 (0.7-1.2) 39 (87) 1.0 (0.9-1.3) 22 (49) 0.9 (0.6-1.5)
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in 2003 and betaPV DNA persistence were of similar magnitude, but non-significant (data 
not shown). Strength of associations did not vary with increasing numbers of prevalent AK 
(data not shown). 
discuss ion
We studied the persistence of betaPV DNA in eyebrow hairs over an 8-year period in a 
broadly representative sample of adults from an Australian community. We then assessed 
prospectively whether such long-term betaPV persistence was a risk factor for the develop-
ment of AKs, after adjustment for presence of AKs at baseline. Among 171 people aged 
30-79 years in 1996, 73% were betaPV-positive for at least one type in 1996 and 85% at fol-
low up in 2003. These prevalences were higher than found in earlier studies in this cohort 
(16;17), probably because of the newer, more sensitive method of betaPV detection used 
here. Half of the participants had at least one betaPV type-specific persistent infection, 67% 
of the people who tested positive in 1996. Of the total betaPV infections at baseline in all 
Table 4: Actinic keratoses in 2007 of 138 Nambour Skin Cancer Study participants of which lesion 
data were available in relation to betaPV detection in 1996, 2003 and at both time points (RR 
adjusted for age, sex and AK diagnosed at baseline).
 AK total body 2007 AK head and neck 2007
 AK + AK-
RR 
(95% CI) AK+ AK-
RR 
(95% CI)
 N (%) N (%)  N (%) N (%)
BetaPV 1996 (all) (n=138) 
- 22 (58) 16 (42)  14 (37) 24 (63)  
+ 72 (72) 28 (28)  62 (62) 38 (38)  
BetaPV 1996 (single detection) (n=71)* 
- 22 (58) 16 (42) 1.0 14 (37) 24 (63) 1.0
+ 20 (61) 13 (39) 1.0 (0.8-1.2) 16 (48) 17 (52) 1.1 (0.6-1.7)
BetaPV 2003 (all) (n=138) 
- 9 (56) 7 (44)  6 (38) 10 (62)  
+ 85 (70) 37 (30)  70 (57) 52 (43)  
BetaPV 2003 (single detection) (n=71)* 
- 9 (56) 7 (44) 1.0 6 (38) 10 (62) 1.0
+ 33 (60) 22 (40) 1.0 (0.8-1.2) 24 (44) 31 (56) 1.0 (0.6-1.7)
BetaPV 1996&2003 (persistence) (n=138) 
- 42 (59) 29 (41) 1.0 30 (42) 41 (58) 1.0
+ 52 (78) 15 (22) 1.0 (0.9-1.2) 46 (69) 21 (31) 1.4 (1.0-1.9)
BetaPV 1996&2003 (persistence) (n=77)** 
- 27 (56) 21 (44) 1.0 32 (67) 16 (33) 1.0
+ 13 (45) 16 (55) 1.0 (0.7-1.5) 14 (42) 15 (52) 1.5 (0.9-2.5)
*In this category only participants with a virus detected at one time point are counted
**People that were AK negative at baseline (1996)
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participants, half of the infections appeared to persist over the 8-year follow-up period. The 
likelihood of betaPV DNA being both present and persisting 8 years later increased with 
age. Except for older age, no other factors were associated with betaPV persistence. We 
postulate that this association of betaPV infection and persistence with older age reflects 
natural deterioration of the immune system with age, known as immune senescence (23). 
Alternatively, contraction of de novo betaPV infections with increasing age might cause the 
observed association, but we consider this option less likely. 
McBride and colleagues performed a study in the same population, assessing AK risk 7 
years after baseline betaPV status had been established (16). We have not only extended 
this period to 11 years but have also assessed association between persistent betaPV infec-
tion and AKs. In the current study, we did not find the effect of betaPV presence in 1996 
on the risk of AKs that McBride found, nor associations between AK and risk factors other 
than age. We also did not find different associations between betaPV infection and AKs in 
men and women, as Boxman and colleagues found in 1996 (17). Again these differences 
may be due to our use of a betaPV test that was able to detect the common low copy number 
infections. The different cohort sizes and time-intervals measured may also have played a 
role.
Indeed a potential limitation of this study was the different methods used for DNA isolation 
of the 1996 and the 2003 samples. Since recent research shows that different isolation 
methods can give different end-results (24), it is possible that the newer and more sensitive 
method used in 2003 partly also explains the higher number of infections that were found 
in 2003 than in 1996 (490 versus 413). On the other hand, based on previous findings it was 
to be expected that the prevalence of betaPV increased with age (15;25). Further, while we 
have referred to the presence of a virus at both time points as “persistent” it is possible that 
infections are labile and the virus was not present through the entire time period. The fact 
that 12% of the negative control samples tested betaPV positive, with no dominant type, 
did not affect our conclusions as this would have resulted in underestimation of betaPV 
persistence. Finally betaPV can occur in very low copy numbers (26), so it is conceivable 
that some viruses were still present in 2003 but were below the detection limit.
There is little knowledge about the long-term persistence of betaPV infections. A previous 
study on betaPV persistence in eyebrow hairs among 23 healthy volunteers aged 21 to 64 
years in The Netherlands showed that 48% of betaPV type-specific infections in 74% of 
chapter 5   83
the study participants were persistent over a period of six months (13). We found lower 
persistence (30% of betaPV infections in 49% of the participants) after 8 years of follow-
up. Apart from our longer follow-up time, the smaller number of betaPV measurements, the 
different DNA purification method and the different geographical region of the Australian 
study group compared with the Dutch, are all likely to have influenced the comparability 
of these results.
A small study in 42 immunocompetent people found that 48% who were positive at base-
line had a persistent infection after 5 to 7 years of follow up (14). In our study the viral 
persistence among those who were betaPV-positive at baseline was 67% (83/124). This 
difference again might be explained by our larger study group, the different geographical 
region, and the different method used for betaPV detection.
With regard to specific betaPV types, we observed that the more prevalent a betaPV type 
was, the more likely it was to persist, although one frequently occurring type (HPV17) 
was only found to persist in 6% of participants. Our overall finding accords with studies 
concerning high-risk mucosal HPV persistence in women (27), where the more prevalent 
HPVs persist more often. While comparisons between mucosal and betapapillomaviruses 
are interesting, the lack of knowledge about the pathophysiology of betaPV infections and 
about the role of the immune system in clearance of these infections does limit conclusions 
that can be drawn. In general however, betaPV persistence appears much more common 
than persistence of mucosal HPV infections in the (ano) genital tract (27). To what extent 
betaPV persistence increases the risk of cutaneous SCC was not determined in this study, 
because the number of incident SCC cases was too small. Similarly, we could not identify 
any betaPV types which unequivocally increased the risk of developing AK. 
The finding that long-term betaPV infection in eyebrow hairs is related to subsequently 
developing AKs on the skin of the head and neck has not been previously reported. We 
observed no association with whole-body AKs in those with the long-term persistent 
betaPV infections. The association between betaPV persistence and AKs on the head and 
neck but not with AKs on the whole body might indicate that betaPV in eyebrow hairs is a 
better marker of infection on the face, neck and scalp than on the rest of the body, despite 
a recent study showing that eyebrow hairs are a good marker of cutaneous infection on 
the body (5;28-30). Previous studies of the association between AK and betaPV did not 
examine head and neck AK in isolation and therefore comparisons cannot be made.
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Overall, we conclude that persistence of betaPV infection in eyebrow hairs over a long 
period of time is common. Our results indicate that persistent infection with betaPV is 
a risk factor for the development of AK; whether it is a risk factor for SCC needs to be 
determined. In contrast, transient infection did not alter the risk of AK. Although these 
findings accord with persistent mucosal HPV infections and increased risk for cervical 
intraepithelial neoplasia and cervical cancer, there are many uncertainties and dissimi-
larities between mucosal and cutaneous HPVs and their role in tumorigenesis. The role of 
betaPV in the development of cutaneous tumors and the importance of duration of betaPV 
infection requires ongoing investigation.
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abst ract
Betapapillomavirus (betaPV) serum antibodies are frequently used as a marker of infection 
in epidemiological studies aiming to elucidate the possible association between betaPV and 
cutaneous squamous-cell carcinoma (SCC). Most previous studies have been case-control 
and their collective results are inconclusive. Therefore we have investigated the relation 
between betaPV antibodies and SCC in a population-based cohort study.
Serum samples were collected in 1992 and/or 1996 from 1311 participants of the 
community-based Nambour Skin Cancer Study. These were tested for the presence of L1 
antibodies from 21 different betaPV types and an age- and sex-adjusted Cox proportional 
hazards model was used to analyse the relation with subsequent SCC occurence from 1992 
until 2007. 
During follow-up SCC was newly diagnosed in 150 people. No associations were found 
between the presence of betaPV L1 antibodies and the occurrence of SCC in longitudinal 
analyses overall (HR for any betaPV infection 1.0), and stratification by sex, skin colour 
and sunburn propensity did not affect these results. However among people who were 
less than 50 years old in 1992, the presence of betaPV antibodies was associated with a 
two-fold increased risk of SCC. There was no significant association between antibodies 
to any individual betaPV types examined (HPV5, 8, 9, 15, 20, 23, 24, 36, 38) and the later 
development of SCC.
Whether betaPV infection of the skin, and indirectly betaPV antibodies, are involved in the 
oncogenic process in the general population remains unclear, but this longitudinal study 
provides some limited support. 
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in t roduct ion
Cutaneous squamous cell carcinoma (SCC) is among the most commonly diagnosed 
cancers in people with fair skin. Human papillomaviruses of the beta-genus (betaPV) are 
non-enveloped cutanotropic DNA viruses that have been associated with the development 
of SCC (1). At present, 31 different betaPV types have been fully sequenced (2-4). 
Epidemiological studies have shown that antibodies against the betaPV major capsid 
antigen, L1, can be found in the serum of patients with SCC or the precursor lesion actinic 
keratosis (AK), but also in people unaffected by these lesions. (5-10). BetaPV L1 antibodies 
have been associated with both SCC and AK in case-control studies (6;10-20) although the 
findings are somewhat inconsistent (reviewed in (14)). The most recent and largest case-
control study found an association between betaPV antibodies and SCC, with an increasing 
risk for antibodies to multiple betaPV types as well as in people using glucocortcoids 
(20). It is difficult to assess the independent effect of specific viruses, due to the very high 
frequency of multiple infection (21), but to date associations have mostly been identified 
between HPV8 and HPV38 and prevalent SCC (11-13;16;17;19). A more recent study also 
found associations with HPV15 and 17 as well as with gammaPV types (18). 
Case-control studies assess betaPV exposure at the same time as, or even after, diagnosis of 
the skin cancer. This prevents assessment of temporality, so the direction of any observed 
association cannot be determined. Longitudinal studies overcome this issue but there has 
been only one report of a prospective pilot study published, in which there was no asso-
ciation found between baseline HPV antibodies and subsequent SCC in 39 patients (14). 
However, as the authors of this paper pointed out, their study did not have adequate power 
to assess the association. 
To further explore the issue we aimed to assess the association between betaPV L1 anti-
bodies and cutaneous SCC using data from a population-based cohort study in Nambour, 
Australia.
mater ia l  and methods
study population and sample collection
Participants were a subset of the study population of the Nambour Skin Cancer Study 
described in detail previously (22-24). Briefly, in 1986, 2095 of 3000 randomly selected 
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residents aged 20-69 of Nambour, a subtropical township in Australia (latitude 26°S), 
participated in a skin cancer prevalence survey. From 1992 to 1996, 1621 of these took part 
in a trial of sunscreen application and beta-carotene supplementation for the prevention 
of skin cancer. All participants received full-body skin examinations by a dermatologist 
in 1992, 1994 and 1996 to ascertain the presence of actinic keratoses, skin malignancies, 
telangiectasia on the face and elastosis of the neck. Skin lesions arising between these 
examinations, and from 1997 to 2007, were ascertained through the local pathology 
laboratories. Participants completed standardised questionnaires about sun exposure and 
other possible risk factors for skin cancer including past history of skin cancer. Blood was 
collected from a randomly selected subsample of participants in 1992 and from all consent-
ing participants in 1996. Participants who were known to have had an SCC prior to their 
first serum measurement were excluded from the study. Ethical approval for all aspects of 
the study was obtained through the Bancroft Centre Human Research Ethics Committee, 
Queensland Institute of Medical Research. 
multiplex serology
We tested serum samples for the presence of antibodies to the major capsid antigen L1 
of HPV 5, 8, 9, 14, 15, 17, 20, 21, 22, 23, 24, 36, 38, 47, 49, 75, 76, 80, 92, 93 and 
96 by multiplex serology. This is an antibody detection method based on a glutathione 
S-transferase capture ELISA, in combination with fluorescent bead technology (25-27). 
Positive serology cut-offs were standardised at 200 MFI (Mean Fluorescence Intensity) (8). 
statist ical analyses
We calculated the prevalence of betaPV antibodies for any betaPV type overall and for each 
of the 21 genotypes tested in 1992 and 1996. We estimated hazard ratios for the association 
between SCC and the presence of any betaPV antibodies, the number of different antibody 
types and selected specific antibody types (HPV5, 8, 9, 15, 20, 23, 24, 36, 38) using a Cox 
proportional hazards model, adjusted for age and sex. The date of entry into the cohort was 
the date at which serum antibodies were first measured (1992 or 1996), and the date of 
censoring was either the date of first SCC diagnosis, the date participant was lost to follow-
up or 31 December 2007, whichever occurred first. If participants had both 1992 and 1996 
serum measurements available, we used both records to allow for changing antibody status. 
A robust sandwich covariance matrix was used to account for intra-person correlation using 
the method described by Lin et al (28). We conducted additional analyses, within strata of 
age, sex, skin colour, and tanning ability. Statistical analyses were performed using SAS 9.1.
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Table 1: Baseline characteristics of participants of the Nambour Skin Cancer Study (n=1311) with 
betaPV antibodies measured in 1992 and/or 1996
 
N (%) 
(n=1311)
Person 
years
Number who 
developed SCC 
(%)
Incidence 
rate /100.000/
person years
adjusted 
HR*
Sex     
F 740 (56) 7805 71 (11) 910 1
M 571 (44) 5845 79 (12) 1352 1.2 (0.9-1.7)
age in 1992 (Y)     
< 50 730 (56) 8190 38 (5) 464 1
50+ 581 (44) 5459 112 (19) 2052 4.4 (3.1-6.4)
skin colour     
olive 89 (7) 1008 3 (3) 298 1
medium 499 (38)
5091
49 (10) 962
3.7 (1.2-
11.6)
fair 722 (55)
7539
98 (14) 1300
5.5 (1.8-
17.0)
when exposed to sun     
only tan 144 (11) 1416 9 (6) 636 1
burn than tan 911 (69) 9627 88 (10) 914 1.3 (1.1-4.4)
always burn, never tan 256 (20) 2594 53 (21) 2043 5.0 (2.5-9.8)
occupational sun exposure     
mainly indoors 584 (45) 6264 57 (10) 910 1
both indoor and outdoor 483 (37) 4938 62 (13) 1256 1.0 (0.7-1.5)
mainly outdoors 244 (19) 2436 31 (13) 1273 1.1 (0.7-1.7)
recreational sun exposure     
mainly indoors 198 (15) 2029 18 (9) 887 1
both indoor and outdoor 573 (44) 5944 64 (11) 1077 1.4 (0.9-2.4)
mainly outdoors 540 (41) 5665 68 (13) 1200 1.2 (0.7-2.1)
Nuchal elastosis     
Limited 292 (22) 3322 7 (2) 211 1
Moderate 639 (49) 6709 63 (10) 939 2.7 (1.2-6.0)
Extensive 376 (29) 3598 78 (21) 2168 4.3 (1.9-9.9)
Telangiectasia face     
Low 384 (29) 4113 30 (8) 729 1
Moderate 628 (48) 6529 71 (11) 1087 1.1 (07-1.7)
Extensive 294 (23) 2962 48 (16) 1621 1.3 (0.8-2.2)
Smoker     
life-long non smoker 800 (61) 8171 78 (10) 955 1
current smoker 148 (11) 1508 15 (10) 995 1.6 (0.8-3.2)
ex-smoker 363 (28) 3970 57 (16) 1436 1.0 (0.6-1.6)
*Hazard ratio adjusted for age and sex
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resu l ts
baseline characterist ics
1311 people were included in this analysis, 176 with only a 1992 blood sample, 655 only 
a 1996 blood sample and 480 with both 1992 and 1996 samples. Their mean age was 49 
years (SD 13, range 25-75) and 44% were men (Table 1). Being aged over 50 years, having 
medium or fair skin colour, a propensity to burn when exposed to the sun and having 
Table 2: Detection of betaPV antibodies overall and for specific betaPV types in 1992 and 
1996, for the whole cohort and restricted to those people with both 1992 and 1996 sera 
available.
 1992 antibodies 1996 antibodies 1992 antibodies 1996 antibodies
 (n=656)* (n=1135)** (n=480)*** (n=480)***
 N (%) N (%) N (%) N (%)
Any betaPV type 409 (62) 748 (66) 300 (63) 329 (69)
     
HPV5 61 (9) 109 (9) 43 (9) 46 (10)
HPV8 220 (34) 346 (30) 159 (33) 173 (36)
HPV9 109 (17) 179 (16) 79 (16) 93 (19)
HPV14 11 (2) 17 (2) 6 (1) 8 (2)
HPV15 155 (24) 253 (22) 112 (23) 119 (25)
HPV17 149 (23) 283 (25) 109 (23) 129 (27)
HPV20 97 (15) 134 (12) 69 (14) 61 (13)
HPV21 119 (18) 207 (18) 82 (17) 97 (20)
HPV22 82 (13) 137 (12) 60 (13) 60 (13)
HPV23 82 (13) 139 (12) 54 (11) 63 (13)
HPV24 107 (16) 174 (15) 77 (16) 84 (18)
HPV36 86 (13) 136 (12) 56 (12) 57 (12)
HPV38 214 (33) 347 (31) 160 (33) 176 (37)
HPV47 85 (13) 134 (12) 56 (12) 59 (12)
HPV49 170 (30) 269 (24) 130 (27) 138 (29)
HPV75 113 (17) 174 (15) 79 (16) 84 (18)
HPV76 103 (16) 149 (13) 75 (16) 72 (15)
HPV80 110 (17) 208 (18) 74 (15) 89 (19)
HPV92 84 (13) 142 (13) 60 (13) 66 (14)
HPV93 21 (3) 29 (3) 15 (3) 12 (3)
HPV96 126 (19) 199 (18) 92 (19) 98 (20)
     
Number of types     
0 247 (38) 387 (34) 180 (38) 151 (31)
1-3 214 (32) 416 (37) 156 (32) 167 (35)
4+ 195 (30) 332 (29) 144 (30) 162 (34)
* All people with 1992 serum sample
** All people with 1996 serum sample
*** All people with 1992 and 1996 serum sample
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a high degree of nuchal elastosis were significantly associated with the development of 
SCC (Table 1). SCC was diagnosed in 150 participants during follow-up. A single SCC 
developed in 97 people, and 53 participants developed more than one (range 2-20). 
betapvl1 antibody prevalence
The overall prevalence of betaPV antibodies in 1992 was 62%, and 46% of participants 
were positive for multiple types (Table 2). The type-specific prevalance was highest 
for HPV8 (34%), HPV38 (33%) and HPV49 (26%). In 1996, 66% of participants were 
betaPV seropositive and 48% were positive for more than one type (Table 2). Type-specific 
prevalence varied from 31% for HPV38 to 1% for HPV14. The overall and type-specific 
prevalances were similar among the 480 people with 1992 and 1996 sera available (table 
2). The betaPV antibody prevalence of the 483 people with serum samples collected in 
1992 and 1996 was generally stable in the intervening 5 years, with only 13% of people 
changing their antibody status between 1992 and 1996. 
betapv antibody-scc associations
No association was found between the presence of betaPV L1 antibodies to at least one 
betaPV type and the development of SCC (RR 1.0, 95% CI 0.7-1.4), or with antibodies 
to multiple types (Table 3). However among people who were less than 50 years old in 
1992, the presence of betaPV antibodies was associated with a two-fold increased risk of 
SCC. This association was not evident in those older than 50 years. Stratification by sex, 
skin colour and burning ability showed no differences in assocations between betaPV risk 
factors and SCC-risk. There was no significant association between any of the individual 
betaPV types examined (HPV5, 8, 9, 15, 20, 23, 24, 36, 38) and the development of SCC 
(Table 4).
discuss ion
The majority of previous studies finding associations between betaPV and SCC of the skin 
have been case-control studies (6;11-13;16;17;19;20;29). In this longitudinal study of 1311 
adults followed over 10 to 15 years we did not observe any association with overall anti-
body positivity, antibodies to multiple betaPV types or to specific types previously shown 
to be associated with SCC. There was however an association among younger adults: those 
under 50 years showed a two-fold increased risk of SCC in the presence of betaPV antibod-
ies.
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Table 3: Relative risks for SCC for the overall population as well as stratified by sex, age, skin type 
and propensity to burn
N (%) Person years
Number of 
participants 
with SCC 
(%)
Incidence 
rate/100.000/
person years
adjusted HR
All* (n=1311)
betaPV AB
- 437 (33) 4727 44 (10) 931 1,0
+ 874 (67) 8894 106 (12) 1192 1.0 (0.7-1.4)
number betaPV AB
0 437 (33) 4727 44 (10) 931 1,0
1-3 478 (37) 4911 61 (13) 1242 1.0 (0.7-1.5)
4+ 396 (0) 3983 45 (11) 1130 0.9 (0.6-1.4)
Men** (n=571)
betaPV AB
- 157 (27) 1715 20 (13) 1166 1,0
+ 414 (73) 4118 51 (12) 1238 0.7 (0.4-1.1)
number betaPV AB
0 157 (27) 1715 20 (13) 1166 1,0
1-3 202 (35) 2052 25 (12) 1218 0.7 (0.4-1.2)
4+ 212 (38) 2066 26 (12) 1258 0.7 (0.4-1.3)
Women** (n=740)
betaPV AB
- 280 (38) 3012 24 (9) 797 1,0
+ 460 (62) 4776 55 (12) 1152 1.3 (0.8-2.0)
number betaPV AB
0 280 (38) 3012 24 (9) 797 1,0
1-3 276 (37) 2859 36 (13) 1259 1.4 (0.9-2.4)
4+ 184 (25) 1917 19 (10) 991 1.0 (0.6-1.8)
< 50 years*** 
(n=730)
betaPV AB
- 255 (35) 2949 8 (3) 271 1,0
+ 475 (65) 5224 30 (6) 574 2.1 (1.0-4.6)
number betaPV AB
0 255 (35) 2949 10 (4) 271 1,0
1-3 256 (35) 2871 15 (6) 522 2.3 (1.0-5.0)
4+ 219 (30) 2353 16 (7) 637 2.1 (0.9-4.9)
50+ years*** (n=581)
betaPV AB
- 182 (31) 1778 45 (24) 2025 1,0
+ 399 (69) 3670 123 (29) 2071 0.8 (0.5-1.2)
number betaPV AB
0 182 (31) 1778 45 (24) 2025 1,0
1-3 222 (38) 2040 65 (28) 2206 0.9 (0.6-1.3)
4+ 177 (31) 1630 58 (31) 1902 0.7 (0.4-1.1)
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The overall prevalence of betaPV antibodies of 62% in 1992 and 66% in 1996 was slightly 
higher than the 51% previously found in a similar population where the same laboratory 
technique and cut-off were used for ascertainment of antibodies (27). As betaPV sero-
positivity increases with age (8;27) and the mean age was lower in this study than in the 
previous Queensland study (27), the relatively high seroprevalence here is not due to older 
age and remains unexplained. The betaPV antibody prevalence of the 480 people with 
Table 3 continued
N (%)
Person 
years
Number of 
participants 
with SCC
Incidence 
rate/100.000/
person years
adjusted HR
Fair skin* (n=722)     
betaPV AB     
- 238 (33) 2650 25 (11) 943 1,0
+ 484 (67) 4873 73 (15) 1498 1.3 (0.8-2.0)
number betaPV AB    
0 238 (33) 2650 25 (11) 943 1,0
1-3 259 (36) 2639 39 (15) 1478 1.3 (0.8-2.1)
4+ 225 (31) 2234 34 (15) 1522 1.2 (0.7-2.0)
Medium/olive skin* (n=588)    
betaPV AB    
- 199 (34) 2078 19 (10) 914 1,0
+ 389 ( 66) 4021 33 (8) 821 0.6 (0.3-1.1)
number betaPV AB    
0 199 (34) 2078 19 (10) 914 1,0
1-3 219 (37) 2272 22 (10) 968 0.7 (0.4-1.3)
4+ 170 (29) 1749 11 (6) 629 0.4 (0.2-1.0)
Always burn* (n=256)    
betaPV AB   1233  
- 79 (31) 892 11 (14) 2475 1,0
+ 177 (69) 1697 42 (24) 1.1 (0.6-2.1)
number betaPV AB    
0 79 (31) 892 11 (14) 1233 1,0
1-3 89 (35) 865 22 (25) 2543 1.4 (0.7-2.7)
4+ 88 (34) 832 20 (23) 2404 0.9 (0.5-1.9)
Burn-tan/only tan* (n=1054)    
betaPV AB    
- 358 (34) 3836 33 (9) 860 1,0
+ 696 (66) 7197 64 (9) 889 0.9 (0.6-1.3)
number betaPV AB    
0 358 (34) 3836 33 (9) 860 1,0
1-3 388 (37) 4046 39 (10) 964 0.9 (0.6-1.5)
4+ 308 (29) 3151 25 (8) 793 0.8 (0.5-1.3)
* Hazard ratio adjusted for age and sex
** Hazard ratio adjusted for age
*** Hazard ratio adjusted for sex
98  chapter 6 
serum samples collected in 1992 and 1996 was quite stable in the short-term (5 years), with 
only around 10% of people changing their antibody status in that time. 
This is the largest longitudinal study to evaluate the relationship between betaPV antibodies 
and SCC, and it is consistent with a small prospective pilot study (cases=39) in the United 
Table 4: Associations between betaPV type-specific seropositivity and SCC
N(%)
(n=1311)
Person years
Number of 
participants
with SCC (%)
Incidence 
rate/100.000/
person years
adjusted HR*
HPV5    
- 1174 (90) 12344 136 (12) 1102 1,0
+ 137 (10) 1278 14 (10) 1095 1.0 (0.5-1.7)
  
HPV8  
- 888 (68) 9329 95 (11) 1018 1,0
+ 423 (32) 4293 55 (13) 1281 1.1 (0.8-1.5)
 
HPV9  
- 1092 (83) 11387 129 (12) 1133 1,0
+ 219 (17) 2235 21 (10) 940 0.7 (0.5-1.2)
  
HPV15  
- 1002 (76) 10522 112 (11) 1064 1,0
+ 309 (24) 3100 38 (12) 1226 1.0 (0.7-1,5)
  
HPV20  
- 1131 (86) 11895 133 (12) 1118 1,0
+ 180 (14) 1727 17 (9) 984 0.6 (0.3-1.0)
  
HPV23  
- 1138 (87) 11973 136 (12) 1136 1,0
+ 173 (13) 1649 14 (8) 849 0.7 (0.4-1.1)
  
HPV24  
- 1011 (77) 11455 128 (13) 1117 1,0
+ 300 (23) 2167 22 (7) 1015 0.8 (0.5-1.3)
  
HPV36  
- 1133 (86) 11887 134 (12) 1127 1,0
+ 178 (14) 1735 16 (9) 922 0.7 (0.4-1.1)
  
HPV38  
- 900 (69) 9386 102 (11) 1087 1,0
+ 411 (31) 4236 48 (12) 1133 0.9 (0.6-1.3)
* Hazard ratio calculated using Cox proportional hazards model and adjusted for age and sex
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Kingdom in that both found no association between baseline serology and incident SCC 
(14). However we did find an association in people diagnosed with SCC who were less than 
50 years at entry into the study. It is possible that SCC diagnosed at younger ages is less 
strongly related to cumulative ultraviolet radiation exposure with other HPV more likely 
to play a role than in older people. No previous studies have reported results stratified by 
age, so we do not know if stronger associations have been apparent in younger age groups 
in previous studies. 
Apart from the association in younger people, our overall results are not in accord with those 
from recent large case-control studies which have showed generally positive associations 
(10-20). Understanding the relation between HPV and skin cancer is hampered by lack of 
knowledge about the appropriate measure of infection. BetaPV are almost ubiquitous on 
the skin, with much higher prevalence of betaPV DNA than of antibodies, so some factor(s) 
other than simply the presence of betaPV on the skin must influence the development of 
antibodies. It has been hypothesised that the presence of SCC (or its precursor lesions, 
actinic keratoses) may result in increased viral load or local inflammation, resulting in 
presentation of the virus to the immune system and seroconversion (6;10;19). If this is the 
case, it is possible that the results of case-control studies do not indicate a causal associa-
tion but are due to “reverse causality”. In support of this, in the previous small longitudinal 
study in the United Kingdom, there was a tendency towards higher seroprevalence in 15 
prevalent cases than in 39 incident cases, although this was not statistically significant. 
However we did not find that a diagnosis of SCC between 1992 and 1996 increased the 
likelihood of seroconversion in our study, and there is also no evidence that the diagnosis of 
AK leads to seroconversion in people without a diagnosis of SCC (Antonsson, unpublished 
data). Furthermore, the lack of association between the presence of antibodies and BCC in 
case-control studies argues against the reverse causality hypothesis (20). 
There may be other biases or uncontrolled confounding that have led to the associa-
tions observed in case-control studies. Assuming that neither bias or reverse causality is 
responsible and that there is a causal relation, the possible reasons for the overall lack of 
association in our longitudinal study need to be considered. It is possible that very high 
levels of sun exposure in Queensland overwhelm any detectable effect of betaPV. However 
we have previously shown that the prescence of persistent betaPV DNA in eyebrow hairs 
is associated with the development of AK in this population (30), providing support for an 
effect of long-term infection. We measured antibody status in mid-adulthood, and although 
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antibodies appear to be relatively stable over a short time period, it is possible that this 
does not reflect the status at the time of initiation of SCC many years earlier. (This limita-
tion would also be true of case-control studies.) Finally, a high proportion of controls in 
this study had been diagnosed with AK. As these lesions are frequently not histologically 
diagnosed, we could not ascertain all AKs occurring during the follow-up period, so could 
not adjust for the presence of AK. The fact that AKs are on the causal pathway between 
sun exposure and SCC, and possibly also between betaPV infection and SCC, may have 
made adjustment inappropriate even had it been possible. The complex interplay between 
betaPV, sun exposure, AK and SCC therefore may be responsible for the lack of association 
between betaPV and SCC in people over 50 at entry into this cohort.
In conclusion, whether betaPV infection of the skin, and indirectly betaPV antibodies, are 
involved in the oncogenic process in the general population remains unclear, but this study 
provides some limited support. Research incorporating measures of immune function and 
genotype, along with multiple measures of betaPV infection and sun exposure, may help to 
elucidate the role of betaPV in cutaneous carcinogenesis. 
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betapapi l lomav i r uses
It is widely believed that betapapillomaviruses (betaPV) are associated with the develop-
ment of actinic keratoses (AK) and cutaneous squamous cell carcinoma (SCC), but to date 
many deficiencies exist in the fundamental knowledge about the natural history of betaPV 
infections as well as about their possible role in keratinocyte skin cancer development. In 
this last chapter, aspects of the natural history of betaPV infections and their association 
with cutaneous SCC development are discussed in view of the new evidence described in 
this thesis and recent findings by others. 
natura l  h is to r y :  acquis i t ion  and t ransmiss ion
Little is known about the transmission of betaPV. In healthy people no clinical signs of ini-
tial or ongoing infection are observable. Prior to the present study described in Chapter 2, 
only 5 other studies, several of which were small with ambiguous findings, had addressed 
the question of transmission of betaPV (1-5). Despite different methods however, all of 
these studies concluded that betaPV transmission probably takes place during close (skin-
to-skin) contact. One of these studies (3) was among tenants in a student share house and 
showed that under these conditions transmission was rare, suggesting that simply living 
in close proximity is not sufficient for betaPV transmission; closer contact is probably 
required in addition.
A more recent study of betaPV transmission in families with an overall HPV prevalence of 
42% found that the frequency of shared types was higher among couples than among ran-
domly selected individuals, but the frequency of sharing at least one type was only 21% and 
in all instances only one type was shared (5). Weissenborn and colleagues (6) studied the 
betaPV-spectrum in 10 families with up to 3 generations sampled over a period of time and 
found comparable results to ours with respect to partner transmission, despite using skin 
swabs instead of eyebrow hairs as the sample for viral DNA detection. Their longitudinal 
measures showed that persistent infections in one person of a family were shared by their 
family members in 30-50% of the cases (6). Thus consistent with other findings, Chapter 
2 (7) showed that cohabiting married or de facto opposite-sex couples more often shared 
betaPV DNA with their opposite-sex domestic partner than with random controls of the 
same age and sex as their partner, drawn from the same population. Again the most likely 
explanation for this finding is the frequent close contact likely to occur between partners, 
as between mothers and babies (1). 
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In Chapter 2 a much higher proportion of couples with at least one shared type (39%) 
was found than in the German study (5), and 14% of these shared more than one type (7), 
possibly due to the higher overall prevalence of betaPV in the Australian sample. The 
higher prevalence might be due to the fact that different PCR and typing methods were 
used in the present study (7) compared with the study by Gottschling and colleagues (5). 
Furthermore, the mean age of participants was higher than in the present study (over 50 
years (5) compared with 42 years (7)), and age is independently associated with betaPV 
acquisition and detection (8).
In view of all the now-available data, it can be concluded that transmission of betaPV DNA 
starts at a very young age and continues through life because of close skin-to-skin contact.
natura l  h is to r y :  p resence and per s is tence
Other aspects of the natural history of betaPV infection are the site distribution of infec-
tion as indicated by the presence of betaPV DNA in different body-tissue samples, the 
persistence of viral DNA and the presence and persistence of betaPV antibodies. In 
epidemiological studies, the presence of betaPV DNA in eyebrow hairs, skin swabs, and 
normal skin biopsies have all been used as markers of betaPV-infection (9-13). Which of 
these is the most appropriate indicator of the betaPV types found in the tumour and/or the 
surrounding area was unknown prior to the study described in Chapter 3. The type-specific 
betaPV prevalence and distribution in 21 sets of four different tissue samples (SCC, per-
ilesional skin, normal skin on the mirror image site of the SCC, and plucked eyebrow 
hairs) taken from incident SCC patients were systematically explored and compared. The 
overall betaPV DNA positivity as well as the multiplicity of infections was high and this 
underscores the ubiquity of cutaneous betaPV infections that has been previously reported 
(3;8;14). The number of betaPV types detected in normal skin was considerably less than 
in the other tissues, in support of previous data showing that normal skin has fewer betaPV 
types than SCC tissue (15;16).
BetaPV is present in hair follicles obtained from different body sites such as scalp, eyebrow, 
arm, trunk, leg and pubic region (9;17). The detection of betaPV in eyebrow hairs has been 
used in epidemiological studies as a marker of infection, not only because of the ease of 
obtaining eyebrow hairs, but also because the bulb is regarded as a reservoir of infection 
(9;18). The greater diversity of types found in hair follicles compared with normal skin 
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lends support to this notion (9), with the epidermal stem cells residing in the bulge as the 
probable main site of persistent infection. 
However, there is limited knowledge about persistence of cutaneous betaPV infection over 
extended periods of time. Furthermore, most epidemiological studies (19;20) have been 
cross-sectional, assessing both betaPV detection in an individual’s eyebrow hairs and their 
skin cancer status at the same point in time. To better address these issues, in Chapter 5 
the persistence of betaPV DNA in eyebrow hairs was studied over an 8-year period. Half 
of the infections present at baseline appeared to persist over the follow-up period and the 
likelihood of betaPV DNA being both present and persisting 8 years later increased with 
age. Except for older age, no other factors were associated with betaPV persistence and it is 
postulated that this association of betaPV infection and persistence with older age reflects 
natural deterioration of the immune system with age, known as immune senescence (21). 
With regard to specific betaPV types, it was observed that the more prevalent a betaPV type 
was, the more likely it was to persist. This finding accords with studies concerning high-
risk mucosal HPV persistence in women (22), where the more prevalent HPVs also persist 
more often. In general, betaPV persistence appears much more common than persistence 
of mucosal HPV infections in the (ano-)genital tract (22). Within a few months after the 
acquisition of viral DNA, a serological response to mucosal HPVs is evoked in about half 
of infected women. In the latter case, the majority of HPV DNA-positive women clear these 
infections within 12 months (23-25). In women with persistent presence of mucosal HPV 
DNA in samples taken at two different occasions, the percentage of seropositive women 
is higher than in women with HPV DNA diagnosed on a single occasion (26). While com-
parisons between mucosal and betapapillomaviruses are interesting, it is recognised that 
the lack of knowledge about the pathophysiology of betaPV infections including the role of 
the immune system in their clearance, limits the conclusions that can be drawn from such 
comparison.
The above mentioned data further raise the possibility that betaPV persistence might also 
be linked to a serological response. Little is known about the association between betaPV 
infection of hair follicles and antibodies in serum. It may be expected that antibodies arise 
as a result of infection of the hair follicles with betaPV DNA, but the specific aspects of 
betaPV infection that drive antibody responses are currently unknown. For example, it is 
feasible that the location, load and persistence of infection, as well as inflammation at the 
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site of infection may all be important in this respect (27;28). In Chapter 4 the associations 
between both prevalence and persistence of betaPV DNA in plucked eyebrow hairs, and 
L1 antibodies in serum were assessed, and it was found that neither DNA measure was 
predictive of antibody detection. Stratification by age, sex, history of sunburns or SCC did 
not alter these findings. Several possible explanations for the observed lack of association 
between betaPV DNA and L1 antibodies can be proposed. Firstly, it may be that the presence 
and/or persistence of betaPV DNA that was measured was not indicative of infection many 
years prior to 1996 and that the antibody response was provoked earlier in life. Secondly, it 
is possible that a high proportion of infections in eyebrow hairs do not evoke an antibody 
response because not all may be indicative of pathologically relevant skin infection. Some 
association has been shown between betaPV DNA found in eyebrow hairs and in biopsies 
of cutaneous SCC and the perilesional skin (Chapter 3) (29;30), but the prevalence in 
eyebrow hairs is substantially higher than in other tissues. Alternatively, or in addition, 
betaPV antibody responses may be associated with the betaPV load rather than simply with 
presence or absence of viral DNA. Lastly, it is possible that antibodies are detected for 
multiple types due to cross-reactivity rather than infection of the skin with those types, and 
thus true type-specific seroresponses may be lower than measured. The high multiplicity 
of L1 antibodies and the significantly higher prevalence of antibody positivity than betaPV 
DNA positivity for 12 types as found in Chapter 4 supports this hypothesis. 
In line with the limited data available on betaPV DNA persistence, stability of betaPV 
antibody status had not been assessed previously. In Chapters 4 and 6 is described that 
betaPV L1 antibody status is very stable when measured over 4 to 8 years. In Chapter 4 
only 11% of people changed their overall betaPV serology status between 1996 and 2003, 
and they had MFI values very close to the cut-off. In Chapter 6 people were followed over 
4 years and only 13% of people changed their serostatus. 
In the view of the data described in this thesis, combined with previous literature it can be 
concluded that eyebrow hairs can still be used as a convenient marker of betaPV infection, 
however it must be acknowledged that only a proportion of the types found might give a 
relevant skin infection. Perilesional skin biopsies can be more useful in that respect, but 
are absent by definition in healthy controls. Although betaPV DNA is often present and 
persistent over years in humans, the presence or persistence of betaPV DNA per se is not 
always sufficient to evoke an antibody response in the infected person. 
chapter 7  111
d isease assoc ia t ions 
BetaPVs are detected frequently in actinic keratoses (AKs) and cutaneous squamous-cell 
carcinomas (SCCs), but have also been found in biopsies from normal skin and eyebrow 
hairs and skin swabs from people with and without skin cancer (1;9;11). Although a number 
of studies have shown statistically significant associations between markers of betaPV 
infection (viral DNA in eyebrow hairs or skin biopsies, and antibodies in serum) and SCC 
(12;19;31-34), and experimental studies have found some evidence of the transforming 
effect of viral (onco)genes of betaPV types (35-40), so far the role of betaPV in skin carci-
nogenesis in vivo has not been fully elucidated. 
Different mechanisms by which betaPV play a role in carcinogenesis have been proposed, 
firstly the “hit-and-run” hypothesis, whereby betaPV act early in carcinogenesis and is 
not necessary for maintenance of the malignant phenotype (41;42). Secondly, betaPV 
may act within or contribute to field cancerisation, where a discrete area of tissue is at 
increased risk of developing cancer (43), as seen for SCC of the oesophagus (44) and 
cutaneous actinic keratoses (45-48). This might be explained by betaPV-mediated impair-
ment of host cell defences against excessive sun light exposure, such as inhibition of DNA 
repair and apoptosis (37;49;50). As already described (in Chapter 3), type-specific betaPV 
prevalence and distribution in different tissues from each of 21 incident SCC patients were 
systematically explored and compared. The lower number of betaPV types found in normal 
skin compared to the tissue near the SCC supports the hypothesis that perilesional skin 
represents an area of field cancerisation from which the tumour arose (45-48). The localised 
presence of betaPV may have contributed to the field change (possibly by its property to 
impair cellular defences against UV-induced DNA damage (51;52)), in conjunction with 
other factors such as sunburn or chronic sun exposure. Alternatively, focal damage may 
have enhanced betaPV infection, increasing the viral load above the detection limit of the 
test or, less likely, may have rendered the affected skin more susceptible to infection with 
betaPV. However, this study was small and cross-sectional, and therefore has limitations 
that have to be taken into account when interpreting its findings.
In Chapter 5 long-term betaPV persistence (described above) was further assessed pro-
spectively, as a risk factor for the development of AKs. No association was observed with 
whole-body AKs in those with long-term persistent betaPV infections, however the finding 
that long-term betaPV infection in eyebrow hairs is related to subsequently developing AKs 
on the skin of the head and neck had not been previously reported. The association between 
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betaPV persistence and AKs on the head and neck but not with AKs on the whole body 
might indicate that betaPV in eyebrow hairs is a better marker of relevant infection on the 
face, neck and scalp than on the rest of the body (9;30;53;54).
To date mainly cross-sectional analyses within case-control studies had been per-
formed to assess the relationship between betaPV L1 antibodies and SCC development 
(20;28;31;32;34;55-58). In Chapter 6 this relationship was assessed in a large longitudinal 
study. While no overall associations were found between betaPV L1 antibodies and the 
later development of SCC, a significant association with betaPV was found in people diag-
nosed with SCC who were less than 50 years old at baseline. Apart from the association 
in younger people, our overall results are not in accord with those from recent large case-
control studies which have showed generally positive associations (12;31;32;34;55-61). 
Understanding the relation between HPV and skin cancer is hampered by lack of knowledge 
about the appropriate measure of infection. BetaPV are almost ubiquitous on the skin, with 
much higher prevalence of betaPV DNA than of antibodies, so some factor(s) other than 
simply the presence of betaPV on the skin must influence the development of antibodies. It 
has been hypothesised that the presence of SCC (or its precursor lesions, actinic keratoses) 
may result in increased viral load or local inflammation, resulting in presentation of the 
virus to the immune system and seroconversion (12;28;32). If this is the case, it is possible 
that the results of case-control studies do not indicate a causal association but are due to 
“reverse causality”. This is supported in the previous small longitudinal study in the United 
Kingdom (59). However in Chapter 6 it was not found that a diagnosis of SCC between 
1992 and 1996 increased the likelihood of seroconversion in our study, and there is also no 
evidence that the diagnosis of AK leads to seroconversion in people without a diagnosis 
of SCC (Antonsson, unpublished data). Furthermore, the lack of association between the 
presence of antibodies and BCC in case-control studies argues against the reverse causality 
hypothesis (34). Besides this, other biases or uncontrolled confouding could have played 
a role in not finding the associations foudn before, for example the very high level of sun 
exposure in Queensland or the high frequenty of AK in the population. The fact that AKs 
are on the causal pathway between sun exposure and SCC, and possibly also between 
betaPV infection and SCC, may have made adjustment inappropriate even had it been 
possible. The complex interplay between betaPV, sun exposure, AK and SCC therefore 
may be responsible for the lack of association between betaPV and SCC in people over 50 
at entry into this cohort.
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conc lud ing remarks
This thesis studied the natural history of betaPV and its possible co-carcinogenic effect 
with sun exposure in the formation of cutaneous SCC and AK. The present evidence sup-
ports earlier assumptions that transmission takes place via close skin contact. Secondly 
persistence of betaPV DNA was shown to be a common occurrence, as was stability of 
antibody status, in the general population studied. Current antibody responses however 
appeared not to directly reflect either current presence of betaPV DNA, or the betaPV DNA 
that were present and persistent in the recent past (in the previous decade). 
On balance the detailed, community-based studies described in this thesis support the 
hypothesis that betaPV does play a role in the formation of a proportion of AK and SCC. 
The evidence could have important implications for skin cancer prevention, while recog-
nizing the established fact that in fair-skinned populations in general, sun exposure remains 
the predominant cause of these tumours. That betaPV DNA is found in different samples 
of skin and eyebrow hairs of SCC cases underscores the ubiquity of background infection; 
the type-specific differences in prevalence between perilesional and normal skin further 
suggest a possible additional effect of betaPV in the field of tumorigenesis (for example 
by inhibiting apoptosis and enhancing cell growth). Persistent betaPV DNA was associated 
with the later development of AK, strongly suggesting that viral persistence is important in 
early skin neoplasia in a proportion of affected people, but not all, since so many healthy 
people with high sun exposure were also seen to have persistent betaPV infections. BetaPV 
antibodies seem not to be directly driven by betaPV DNA and were associated with SCC 
development only in people under 50 years.
The precise elucidation of the existence and nature of the association under study, and 
answers to other important questions are yet to be understood nearly forty years after the 
first description in the literature (62) of the possible role of betaPV in cutaneous squamous 
cell carcinoma development. Such questions are, for example, why only some betaPV 
infections are potentially pathogenic, and what are the immunological (and other) char-
acteristics of those who may be susceptible to the co-carcinogenic effects of this virus in 
the skin. From an epidemiological viewpoint, large prospective cohort studies over several 
decades, involving all betaPV measurements (eyebrow hairs, skin biopsies and serum) and 
complemented by in vitro searches for a mechanism whereby betaPV could help activate 
cutaneous neoplasia, are required to resolve the issues definitively. In view of design and 
costs however, the likelihood that such studies can take place in the near future is probably 
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low, but they are needed because only then will we have a basis for believing that, alongside 
sun protection, prevention of betaPV infection may be a useful strategy, as it is in preven-
tion of ano-genital cancers by the high-risk mucosal HPV types, in skin cancer prevention.
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Dit proefschrift beschrijft onderzoek naar de relatie tussen betapapillomavirussen (betaPV) 
en het cutane plaveiselcelcarcinoom (PCC) en diens voorloper actinische keratose (AK). 
BetaPV maken deel uit van de papillomavirusfamilie, die meer dan 100 humane papillo-
mavirussen (HPV) omvat en meerdere animale. HPV is geassocieerd met anogenitale car-
cinomen en cutane wratten. In 1972 werd een associatie tussen betaPV en PCC beschreven 
in patiënten met de zeldzame erfelijke huidziekte Epidermodysplasia Verruciformis (EV). 
Momenteel zijn 31 typen BetaPV bekend (HPV5, 8, 9, 12, 14, 15, 17, 19, 20, 21, 22, 23, 
24, 25, 36, 37, 38, 47, 49, 75, 76, 80, 92, 93, 96, 98, 99, 100, 104, 105 en 113) en nieuwe 
types worden regelmatig beschreven. Associaties zijn beschreven tussen AK en PCC en de 
aanwezigheid van betaPV DNA in wenkbrauwharen, huiduitstrijken en L1 antilichamen.
Voor dit onderzoek zijn wenkbrauwharen gebruikt om betaPV DNA uit te isoleren en bloed 
om antilichamen tegen betaPV te isoleren. Hoofdstuk 2, 4, 5 en 6 zijn uitgevoerd binnen 
de context van de Nambour Skin Cancer Study, een prospectieve cohortstudie naar het 
voorkomen van huidkanker in Nambour, een stad met 10.000 inwoners op 2 uur rijden 
van Brisbane, Australië. Huidkanker komt hier veel voor vanwege de tropische ligging 
en voornamelijk blanke bevolking. Hoofdstuk 3 is uitgevoerd onder PCC-patiënten in 
Townsville, Australië. Ook hier zorgt de hoge UV-belasting en de blanke bevolking voor 
een hoog huidkanker cijfer.
In Hoofdstuk 2 is gevonden dat samenwonende partners vaker dezelfde types betaPV 
hebben wanneer ze vergeleken worden met leeftijd- en geslacht-gematchte controles. Dit 
is een aanwijzing dat betaPV overgedragen wordt via nauw contact. In Hoofdstuk 3 is 
onderzocht hoe vaak betaPV DNA voorkomt in biopten van PCC, de huid rondom de tumor 
(perilesionale huid), gezonde huid en wenkbrauwharen van 21 PCC-patiënten. Gevonden 
werd dat het gemiddelde aantal betaPV types significant hoger was in biopten van PCC 
en perilesionale huid dan in de biopten van normale huid. Dit suggereert dat er sprake is 
van een “field change” van waaruit het PCC ontstaat. Of betaPV daarbij een rol speelt kan 
hieruit niet worden opgemaakt. Ook werd gevonden dat betaPV types in wenkbrauwharen 
redelijk goed overeenkomen met de types die in de tumor worden gevonden. Wenkbrau-
wharen kunnen dus gebruikt worden als maat voor betaPV infectie in de tumor. In Hoofd-
stuk 4 werd gevonden dat de reactie van het lichaam om betaPV L1 antilichamen aan te 
maken niet alleen bepaald wordt door de aanwezigheid van betaPV in gezonde huid. Ook 
langdurige aanwezigheid van betaPV (gedurende 8 jaar), was niet geassocieerd met betaPV 
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L1 antilichamen. Waarschijnlijk zijn additionele stimuli nodig om tot antilichaamproductie 
over te gaan, zoals een overmaat aan aanwezig virus. In Hoofdstuk 5 is onderzocht hoe 
vaak persistentie van betaPV voorkomt onder gezonde Australiërs en of het hebben van 
persistent betaPV het risico op het krijgen van AK verhoogd. Gevonden werd dat 30% van 
de virussen na 8 jaar nog aanwezig zijn (persisteren). Mensen die ouder zijn dan 60 jaar 
hadden tweemaal zoveel kans op een persistente betaPV infectie. BetaPV persistentie was 
geassocieerd met het hebben van AK in het gelaat. In Hoofdstuk 6 is onderzocht of L1 anti-
lichamen geassocieerd zijn met PCC in een longitudinale studie, aangezien eerder alleen 
dwarsdoorsnede onderzoek is uitgevoerd. Gevonden werd dat alleen in de groep patiënten 
onder de 50 jaar een associatie bestond tussen betaPV en het optreden van PCC. Associaties 
binnen de gehele patiëntengroep of met individuele types werden niet gevonden. 
Alles in overweging nemend ondersteunen de studies in dit proefschrift de hypothese dat 
betaPV geassocieerd zijn met de ontwikkeling van AK en PCC. Dit zou consequenties kun-
nen hebben voor de preventie van PCC, hoewel moet worden benadrukt dat UV-expositie 
in de blanke populatie de belangrijkste risicofactor blijft. Persistentie zou de rol van betaPV 
in de oncogenese kunnen versterken, echter persistente infecties worden ook vaker bij 
gezonde personen gevonden.
Bijna 30 jaar na de eerste publicatie over de associatie tussen betaPV en PCC blijven 
belangrijke vragen bestaan. Deze zijn bijvoorbeeld waarom maar een klein deel van de 
infecties potentieel pathogeen lijkt te zijn en welke overige (immunologische, genetische 
of andere) factoren een rol spelen bij de individuele vatbaarheid van een persoon voor 
een co-carcinogeen effect in de huid. In het algemeen is meer in vitro onderzoek naar het 
mechanisme hoe betaPV kan bijdragen aan de ontwikkeling van cutane tumoren van groot 
belang. Idealiter worden daarnaast grote epidemiologische studies met diverse materialen 
(wenkbrauwharen, huidbiopten en serum) uitgevoerd om meer duidelijkheid te verkrijgen 
over de rol van betaPV in het ontstaan van huidkanker. 
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